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This thesis describes three separate but related projects exploring how herpes 
simplex virus 1 (HSV-1) induces and copes with a pro-oxidant environment during 
infection. We found that the UL6 portal ring, the conduit responsible for the uptake and 
release of viral DNA, required disulfide bonds for ring formation and stability. 
Mutagenesis studies revealed that these disulfide bonds might be mediated by 
cysteines 166 and 254. We next examined the protein UL32 as a potential virally 
encoded oxidoreductase. UL32 contains three C-X-X-C motifs reminiscent of proteins 
that regulate disulfide bond formation. Mutation of two of these C-X-X-C motifs 
abrogated protein function. We used a thiol-alkylation assay to show that viral capsid 
proteins, including UL6, had altered disulfide bond profiles in the absence of UL32, 
suggesting that UL32 influences disulfide bond formation in capsid proteins during 
assembly and maturation. We then confirmed that HSV induces oxidation using a 
redox-sensitive GFP probe. We also found that treating HSV-infected cells with the 
antioxidant glutathione (GSH) inhibited viral growth. This growth defect was likely due to 
delayed viral protein expression and replication compartment formation. We further 
investigated the role of ROS generating NADPH-oxidases (NOXs), which are important  
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for the growth of several viruses. Using a pan-NOX inhibitor, we found similar defects in 
viral growth, protein expression and replication compartment formation as observed with 
GSH treatment, suggesting that NOX-derived ROS might be important for HSV 
infection. Collectively, we propose that HSV has evolved to use and manipulate the 
intracellular redox-balance for its own benefit.   
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Chapter 1 
Introduction 
 
General overview 
Herpes simplex virus 1 (HSV-1) is one of many enveloped, double stranded 
DNA (dsDNA) viruses that constitute the Hepresviridae family, which include some 
of the most ancient and ubiquitous viruses in nature. Herpesviruses have been 
recognized since ancient times and were named by Hippocrates based on the 
“creeping” morphology of the lesions caused by the herpes simplex virus 2 (HSV-2). 
Beginning in the early 1900’s, advances in laboratory and virological techniques 
allowed intensive studies into the herpesviruses, and to this day over 200 have been 
isolated and characterized, with the numbers likely to increase with the availability of 
better sequencing technologies. Although herpesviruses have been recognized and 
studied for centuries, there are still a surprising number of questions that remain.  
Nine herpesviruses are known to cause disease in humans (Table 1-1) and 
the disease presentation can range from minor lesions, as in the oral fever blisters 
observed in HSV-1, to very serious manifestations, such as lymphomas (EBV) and 
sarcomas (KSHV). It is currently estimated that over 90% of adults are infected with 
at least one herpesvirus, with many people carrying up to five (Wald and Corey 
2007, Yamanishi, Mori et al. 2013). The long co-evolutionary history of these viruses 
with humans has likely resulted in attenuated pathogenicity; however, they still 
cause significant disease, especially in immunocompromised individuals.  
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Formal	  name	   Synonym	   Sub	  
family	  
Predominant	  
Disease	  
association	  
Human	  	  
Herpesvirus-­‐1	  
Herpes	  simplex	  
virus-­‐1	  
α	   Oral	  fever	  blisters	  
	  
Human	  
Herpesvirus-­‐2	  
Herpes	  simplex	  
virus-­‐2	  
α	   Genital	  warts	  
Human	  
Herpesvirus-­‐3	  
Varicella-­‐zoster	  
virus	  
α	   Chickenpox,	  
Shingles	  
Human	  
Herpesvirus-­‐4	  
Epstein-­‐Barr	  virus	   γ 	   Infectious	  
mononucleosis,	  
Burkitt’s	  
Lymphoma	  
Human	  
Herpesvirus-­‐5	  
Cytomegalovirus	   β 	   Congenital	  
infections	  
Human	  
Herpesvirus-­‐6A	  
Human	  Herpesvirus-­‐
6A	  
β 	   Unclear	  
Human	  
Herpesvirus-­‐6B	  
Human	  Herpesvirus-­‐
6B	  
β 	   Roseola	  
Human	  
Herpesvirus-­‐7	  
Human	  Herpesvirus	  
7	  
β 	   Roseola,	  febrile	  
respiratory	  disease	  
Human	  
Herpesvirus-­‐8	  
Kaposi’s	  sarcoma-­‐
associated	  
Herpesvirus	  
γ 	   Kaposi’s	  Sarcoma	  
Table 1-1 The Human Herpesviruses 
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Furthermore, it has been shown that infection with herpesviruses can contribute to 
increased infection rates of other serious pathogens, such as HIV, HPV and KSHV 
(Lusso, De Maria et al. 1991, Corey, Wald et al. 2004, Smith 2004, Freeman, Weiss 
et al. 2006, Abu-Raddad, Magaret et al. 2008, Qin, Feng et al. 2011).  
Although significant diversity exists among herpesviruses, several 
morphological features are shared within this family of viruses, including a dsDNA 
genome protected by an icosahedral proteinacious capsid, a layer of tegument 
proteins and a glycoprotein-rich lipid envelope. Several aspects of the viral life cycle 
are also shared by all herpesviruses. A well recognized trait of the herpesviruses is 
their ability to establish lifelong infections in which they exist in a latent, or dormant, 
state with periodic episodes of reactivation. Herpesviral DNA synthesis occurs in the 
nucleus during lytic infection.  Upon induction of latency, viral genomes circularize 
and acquire chromatin (Roizman, Knipe et al. 2013). A final property shared by 
herpesviruses is that they carry genes that code for their own replication machinery 
and protein modifying enzymes, such as kinases. (Pellett and Roizman 2013) 
In addition to the common characteristics shared by all herpesviruses, there 
are distinguishing characteristics in viral life style that have resulted in their 
classification into three subfamilies: the alpha, the beta and the 
gammaherpesviruses. Viruses within these subfamilies are defined according to 
their host range, tissue tropism and resulting disease. Alphaherpesviruses (HSV-1, 
HSV-2 and VZV) are the most widely studied and are characterized by short, 
destructive lifecycles and a variable host range (Pellett and Roizman 2013). These 
viruses establish latency in neuronal ganglia and, upon reactivation, generate 
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infectious virions that are released from nerve endings. This results in lytic infection 
of the surrounding cells in the tissue, including fibroblasts and epithelial cells, 
leading to tissue destruction. 
The betaherpesviruses (CMV, Human herpesvirus 6A, Human herpesvirus 6B 
and Human herpesvirus 7) are recognized by restricted host range and their long 
reproductive cycle. Infection with betherpesviruses results in the enlargement of the 
host cell. There are two genera within the human betaherpesvirus subfamily which 
are distinguished by tissue tropism. CMV, a member of the Cytomegalovirus genus, 
can establish latency in myeloid progenitor cells (Reeves and Sinclair 2008) and 
possibly other cell types, but this is still a controversial and poorly understood area 
of investigation. Several cell types are susceptible to CMV infection, including 
endothelial, epithelial, myeloid cells and, to a lesser extent, fibroblasts. Fibroblasts 
are typically used to culture and study CMV, and the lab-adapted strains have been 
shown to accumulate mutations that make them grow more efficiently in this cell type 
(Dargan, Douglas et al. 2010). The other human betaherpesviruses, HHV-6A, 6B 
and 7, are members of the Roseola genus, and they typically infect lymphocytes. 
HHV-6A and 6B were designated as two separate viruses in 2012 due in part to 
differences in their abilities to replicate in specific subtypes of differentiated T-cells 
(Yamanishi, Mori et al. 2013). HHV-7 establishes latency in activated CD4+ T-cells; 
whereas, the reservoirs of HHV-6A and HHV-6B are still being studied (Mori and 
Yamanishi 2007).  
The human gammaherpesviruses include EBV and KSHV which preferentially 
infect B- and T- cells, respectively, although these viruses can infect epithelial cells. 
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EBV can establish latency in both epithelial and B-cells and exhibits a unique 
characteristic of existing in one of three latency states within B-cells. The state of 
latency is determined by the viral proteins being expressed which, in turn, influence 
the growth properties of the B-cell (Amon and Farrell 2005) , including 
transformation of the B-cells (Yates, Warren et al. 1985). KSHV, the most recently 
identified herpesvirus, is the causative agent of Kaposi’s sarcoma and is associated 
with several lymphoproliferative diseases, such as primary effusion lymphoma and 
multicentric Castleman’s disease. It is believed that latency drives transformation 
and hyperproliferation; however, unlike EBV, latent KSHV cannot transform cells in 
culture. Another interesting phenomenon is that cells harboring a latent KSHV 
genome will lose that genome after several passages in cell culture. Thus, it has 
been proposed that persistent infection relies on a combination of latent and lytic 
infection (Damania and Cesarman 2013).  
 Of all the herpesviruses, HSV has proven to be one of the most important 
tools for virologists over the past century. Studies on HSV have led to important 
observations that have not only advanced our understanding of the biology of 
enveloped, DNA viruses, but have also been integral in uncovering virus-host 
interactions involved in disease. HSV, like all viruses, needs to usurp cellular 
metabolic processes for it’s own proliferation. During this process it has to combat 
cellular antiviral mechanisms, the host immune response and keep the cell alive long 
enough to maximize virus production. Conversely, the cells and the organism have 
developed many strategies to limit virus replication and spread. This dynamic has 
led to a molecular arms race, where both the virus and host have been forced to 
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adapt to each other throughout evolutionary time. Thus, viruses have served an 
important role in shaping cellular biology. The study of viruses not only allows us to 
understand how to develop therapeutics to specific microbes but gives us important 
insight to cellular processes that may have evolved to be antiviral but now serve 
other, essential functions. This thesis explores how HSV influences and navigates 
one of these processes - the cellular redox system. Here, we provide evidence that 
HSV-1 induces cellular oxidation, which may have initially involved as an antiviral 
response for its own benefit. We also provide examples of strategies the virus has 
evolved to survive in this altered cellular milieu.  
 
The HSV virion 
The mature HSV virion measures ~200nm and, like all herpesviruses, 
contains a DNA-filled capsid, a layer of tegument and a host-derived lipid envelope. 
The virion protects the viral DNA from the hostile extracellular environment and 
serves as the vehicle to deliver the genome to a susceptible host cell. The isolated 
virion carries ~30 viral proteins as well as several host proteins. The viral proteins 
were originally named VP, meaning “virion polypeptide”, which is a term that is still 
used for some of the proteins (ie. VP5) with the number corresponding to the relative 
banding position of virion proteins on an SDS-PAGE gel.  Some viral proteins are 
called ICP for “Infected Cell Protein”, and these were characterized by the banding 
patterns of whole cell lysates from infected cells. Another commonly used naming 
strategy, and the one most widely used now, is to name the protein based on the 
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location of its open reading frame within the unique long or short arms of the HSV 
genome (ie. UL32 or US1).  
 
The genome 
The 152 kilobase pair genome is packaged as a linear duplex molecule and 
codes for ~90 known gene products. The genome is divided into two covalently 
linked segments that are termed the unique short (US) and the unique long (UL). In 
1988, McGeoch et al mapped the open reading frames within the UL segment, 
numbering them sequentially from left to right (McGeoch, Dalrymple et al. 1988). 
The unique segments are bracketed by inverted repeat regions such that the 
genome arrangement is ab-UL-b’a’a’c’-US-ca (Fig. 1-1) where the terminal a 
sequences are in the same orientation and the a’ sequences within the junction are 
inverted (Wadsworth, Jacob et al. 1975, Wagner and Summers 1978). Sequences 
within the terminal repeats are essential for the encapsidation, or packaging, of the 
viral DNA (Jenkins and Roizman 1986). The cis- acting elements within the a 
sequence required for packaging are discussed in more detail below.  
A unique feature of the genome is the presence of nicks and gaps in DNA 
isolated from virions. When virion DNA is transfected into cells, the nicks and gaps 
elicit a DNA damage response by activating the sensing kinase DNA-PK which must 
be overcome by the virus to establish infection, as shown in recent work from our lab 
(Smith, Reuven et al. 2014). It is somewhat surprising that the virus would evolve to 
have elements, such as a nicked and gapped genome, that would make it easily 
detected by the host. The role of the nicks and gasp in the genome is unclear, but it  
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USULa  b b’a’a‘c’ c’a’
DR1
Pac2 Pac1
OriL
OriS OriS
Figure 1-1 Diagram of the HSV-1 genome. The 152 kbp genomes cantains two unique segments, 
UL and US, that are flanked by reat regions. The genome has three origins of replication that are 
recognized by the origin binding protein, UL9. Pac1 and Pac2 sites are contained within the terminal 
a sequences and are essential for the cleavage and packaging of viral DNA.
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is possible that they play a role in viral DNA replication. Alternatively the nicks and 
gaps may facilitate viral DNA packaging. Our lab is currently investigating these 
possibilities. 
 
The HSV capsid 
The HSV-1 capsid is an icosahedral proteinaceous shell that is mainly 
composed of the major capsid protein VP5 and the minor capsid proteins VP19c, 
VP23 and VP26 (Fig 1-2). VP5 monomers form capsomers with hexameric and 
pentameric geometries that ultimately form the capsid shell made predominantly of 
hexons, with pentons at eleven of the twelve capsid vertices. The capsomeres are 
held together by VP19c and VP23 which exist in a 1:2 stoichiometry to form a 
complex called the triplex (Newcomb, Trus et al. 1993). The smallest minor capsid 
protein is VP26, and this protein associates exclusively with hexonal VP5 in a 1:1 
ratio (Wingfield, Stahl et al. 1997). VP26, unlike the other capsid proteins, isn’t 
essential for growth in cell culture; however, work in a mouse model shows that 
VP26 is important for efficient infection in vivo, especially within the trigeminal 
ganglia (Desai, DeLuca et al. 1998). Another feature of the outer capsid is a ring 
made from twelve monomers of the UL6 protein which occupies one of the capsid 
vertices and is presumed to form a portal responsible for the uptake and the release 
of the viral DNA (Newcomb, Juhas et al. 2001, Trus, Cheng et al. 2004, Cardone, 
Winkler et al. 2007, Chang, Schmid et al. 2007).  
 During infection, the capsid forms prior to DNA packaging. This capsid, called  
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Figure 1-2 The anatomy of the HSV-1 capsid. The HSV-1 capsid is predominantly 
made up of the major capsid protein VP5 (red). The minor capsid proteins VP19c and 
VP23 form a complex (green and yellow) and hold the VP5 hexons and pentons together. 
VP26 (blue) associates with the distal tips of VP5 and may play a role in intracellular 
trafficking.
(J. Conway and F. Homa, 2011, Alphaherpesviruses)
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the procapsid, requires an internal scaffold comprised of the UL26 and the co-  
terminally expressed UL26.5 gene products. Procapsids contain 10-fold more 
UL26.5 than UL26 (Homa and Brown 1997) (Table 1-2). Both UL26 and 26.5 share 
the last 329 amino acids, however, full-length UL26 contains a viral protease (VP24) 
at the N-terminus which is responsible for the cleavage and release of the internal 
scaffold during genome packaging (described below). The scaffold interacts with 
VP5 and UL6 and is an important determinant in the formation and the size of the 
capsid (Newcomb, Thomsen et al. 2003). In 1994, several groups were able to 
assemble capsids in vitro from proteins individually expressed in insect cells infected 
with recombinant baculovirus individual capsid proteins (Newcomb, Homa et al. 
1994, Tatman, Preston et al. 1994, Thomsen, Roof et al. 1994).	  Many studies have 
subsequently used this technology to uncover the minimum requirements for capsid 
formation, as well as to identify many important interactions that make this process 
possible (Newcomb, Homa et al. 1994, Tatman, Preston et al. 1994, Thomsen, Roof 
et al. 1994, Homa and Brown 1997, Newcomb, Homa et al. 2001, Newcomb, 
Thomsen et al. 2003).   
 Although the composition of the capsid has been well-defined, it is still 
unknown exactly how it is formed in vivo. Another mystery is how the UL6 portal is 
incorporated at only one vertex. It has been shown that the UL6 portal is 
incorporated into the capsid at an early step during capsid assembly, and thus is 
believed to be a nucleating factor (Newcomb, Homa et al. 2005). This would suggest 
that the UL6 rings forms prior to the rest of the capsid, leading to more questions as 
to how the portal itself is formed. Our lab has found that a leucine zipper region 
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within the UL6 protein is important for self-interaction and portal ring formation 
(Nellissery, Szczepaniak et al. 2007). In this thesis (Chapter 2), we show that 
disulfide bond formation is another essential binding interaction for portal ring 
formation and stability (Albright, Nellissery et al. 2011). 
 
The envelope and tegument 
The viral envelope consists of a lipid bilayer and at least twelve viral 
glycoproteins are embedded within the host-derived lipid bilayer. Since the 
glycoproteins gB, gD, gH and gL are the only ones required for growth in cell culture, 
and consequently the most widely studied, these will be the only ones noted here 
(Reske, Pollara et al. 2007). When exiting the nucleus, the virus buds through the 
inner nuclear membrane where it obtains an initial envelope. This envelope fuses 
with the outer nuclear membrane, depositing the naked capsid into the cytoplasm. 
The virus then acquires a golgi-derived envelope, which remains part of the virion 
until the subsequent round of infection. This is supported by the observation that the 
composition of the lipids within the viral envelope is consistent with the lipids found 
in golgi-derived membrane (van Genderen, Brandimarti et al. 1994).   
The tegument is the layer between the capsid and the envelope and 
comprises ~20 proteins that are involved in every aspect of the viral lifecycle - from 
physical viral processes, such as capsid transport, to inhibiting cellular antiviral 
activities. Most of the tegument is deposited into the cytoplasm along with the viral 
capsid upon fusion of the viral envelope with the host membrane. Some tegument 
proteins associate with the capsid, such as UL36 and UL37, and are required for 
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targeted transport to the nucleus and subsequent release of the genome through the 
nuclear pore (Batterson, Furlong et al. 1983, Ojala, Sodeik et al. 2000, Copeland, 
Newcomb et al. 2009). Other proteins set the stage for infection. For instance the 
virally encoded ubiquitin ligase, ICP0, may inhibit the innate antiviral response 
through degradation of key cellular proteins while the transactivators ICP4 and VP16 
initiate viral gene expression (Roizman, Knipe et al. 2013). Although there are many 
other important tegument proteins, they will not be discussed here and are reviewed 
elsewhere (Kelly, Fraefel et al. 2009).  
 
The HSV lifecycle 
 
Entry 
The initial recognition of host cells is mediated by gB and gC, which initially 
bind to heparin sulfate proteoglycans, followed by attachment of gD to the 
herpesvirus mediated entry receptor (HVEM), Nectin-1, or 3-O-Sulfated heparin 
sulfate (3-OS HS) (Spear, Eisenberg et al. 2000, Roizman, Knipe et al. 2013).  Once 
the virus attaches, the virus can enter by fusion with the plasma membrane or 
through an endocytic pathway, which is primarily determined by cell-type (Qie, 
Marcellino et al. 1999, Milne, Nicola et al. 2005, Nicola, Hou et al. 2005). Although 
entry mechanisms vary, they all require the formation of a four protein complex 
mediated by the interactions of gD with the class III fusion protein, gB, and the gH/gL 
complex. The gB/gH/gL complex is likely responsible for the actual fusion event, 
however this process is still unclear (Eisenberg, Atanasiu et al. 2012).  
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 Following entry, dynein motors associate with the minor capsid protein VP26 
and possibly the tegument proteins UL36 and UL37 to transport the capsid to the 
nucleus (Sodeik, Ebersold et al. 1997, Douglas, Diefenbach et al. 2004, Wolfstein, 
Nagel et al. 2006) where it docks with the nuclear pore complex, followed by release 
of the genome, most likely through the UL6 portal, into the nucleus (Copeland, 
Newcomb et al. 2009). How this event is coordinated is still a mystery. We have 
shown that disulfide bonds are important for the formation and stability of the UL6 
ring, and it is possible that these interactions are disrupted upon entering the 
reducing environment of the cytoplasm, thus serving as a molecular trigger for 
genome release (Albright, Nellissery et al. 2011). Once the genome is inside the 
nucleus, the host cell and the virus will partake in a molecular tug of war that will 
result in either the onset of a lytic infection or the establishment of latency. 
 
Viral gene expression 
During lytic infection, viral gene expression occurs in a stepwise, orderly 
manner. Immediate early (IE) genes are the first kinetic class and are expressed 
soon after the genome enters the nucleus, a process independent of de-novo protein 
synthesis. The five IE genes are ICP0, ICP4, ICP22, ICP27 and ICP47. ICP0 is an 
E3 ubiquitin ligase that aids in gene expression mostly by counteracting the cellular 
antiviral response. ICP4 is the major viral transcription factor and activates the 
transcription of most of the viral genes (Wagner, Bayer et al. 2013). It also represses 
the expression of a number of viral genes, including itself (DeLuca 2011). Thus, 
ICP4 is required for nearly every step of infection. ICP27 is a multifunctional protein 
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involved with recruiting RNA pol II to sites of gene transcription, inhibiting cellular 
mRNA splicing, and transport of viral mRNAs (Roizman, Knipe et al. 2013). ICP27 
has been shown to work in coordination with ICP4 and ICP0 to activate or repress 
viral genes (Sekulovich, Leary et al. 1988, Rice and Knipe 1990). Thus, ICP27 works 
on many levels to shift the cellular machinery in favor of viral gene expression. 
ICP22 is the least well understood IE gene product and is required for efficient 
infection in animal models; however, it is not required in all cell types. ICP22 may 
play a role in regulating gene transcription and this is due to its influence on the 
phosphorylation status on the C-terminal domain of RNA pol II (Rice and Fraser 
2006). An interesting property of ICP22 is its ability to reorganize the molecular 
chaperone Hsc70 into nuclear inclusions. These inclusions, called VICE domains 
(Virus-Induced Chaperone-Enriched) contain several chaperones as well as 
components of the cellular protein quality control machinery, such as the 20S 
proteasome, and ubiquitinated and misfolded proteins (Burch and Weller 2004, 
Livingston, DeLuca et al. 2008, Livingston, Ifrim et al. 2009, Bastian, Livingston et al. 
2010, Weller 2010). The role of VICE domains is unclear, although our lab is 
intrigued by the possibility that these inclusions might serve to sequester the 
molecular chaperones, especially Hsc70, away from possible antiviral functions.  
The fifth IE gene, ICP47 modulates the immune response by inhibiting antigen 
presentation (Fruh, Ahn et al. 1995, Hill, Jugovic et al. 1995).  
The early genes are the next wave and these code for a number of proteins. 
Most notably, all of the replication proteins are expressed at this time. Late gene 
expression follows and this class is further divided into genes that express with 
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early-late or true-late kinetics. Early-late proteins can be detected in the absence of 
viral DNA replication, however, their expression levels increase at the onset of 
replication. True-late genes, on the other hand, require viral DNA replication; 
proteins are classified as true-late if their expression cannot be detected during 
infection with a DNA replication-defective mutant or during treatment with a viral 
polymerase inhibitor, such as phosphonoacetic acid (PAA). An example of this is 
shown in Chapter 3, where we confirm on the protein level that the DNA packaging 
protein, UL32, is indeed a true-late gene (Albright, Kosinski et al. 2015). The 
structural genes are mostly expressed in the late class and are discussed elsewhere 
in this thesis.  
 
Viral DNA replication 
 HSV viral DNA replication requires seven virally encoded proteins and occurs 
in the nucleus of the cell within globular domains called replication compartments.  
The ssDNA binding protein, ICP8, plays a critical role in the formation of replication 
compartments which begin as small foci, called prereplicative sites, and coalesce to 
fill up the nucleus as the infection progresses (Roizman, Knipe et al. 2013). 
Prerepicative sites contain ICP8, the origin-binding protein UL9, and the three 
subunit helicase/primase complex. It is believed that UL9 and ICP8 mediate the 
distortion of the DNA at any one of three origins of replication that are present in the 
genome (labeled OriS and OriL, Fig. 1-1). The model predicts that this distortion 
would recruit the three subunit helicase/primase (H/P) complex which would in turn 
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recruit the viral polymerase (UL30) and its processivity factor (UL42) (Weller and 
Coen 2012).  
 The end product of DNA synthesis is a longer than unit-length concatemer 
and there are a few models for how this is formed. As opposed to the long held 
belief that the HSV genome circularizes and that concatemers are formed through a 
rolling-circle replication mechanism, we and others have observed that 
recombination of the viral DNA might play a significant role in concatemer formation. 
Some lines of evidence include: 1) replicating viral genomes are complex, branched 
and don’t enter a pulsed-field gel, 2) the virus encodes two proteins (ICP8 and 
UL12) that may work as a two-subunit recombinase, 3) recombination is a frequent 
event between two co-infecting genomes and 4) HSV-1 activates some 
recombination pathways while disabling others (Bataille and Epstein 1994, Severini, 
Morgan et al. 1994, Zhang, Efstathiou et al. 1994, Martinez, Sarisky et al. 1996, 
Severini, Scraba et al. 1996, Schumacher, Mohni et al. 2012).  
 
DNA packaging 
 One of the last steps of the viral lifecycle before egress from the nucleus is 
the packaging of viral DNA into the capsid, which, like almost all intranuclear viral 
events, occurs within replication compartments. This multistep process involves a 
preformed procapsid acquiring a full-length genome with the concurrent proteolysis 
and expulsion of the internal scaffold by the viral protease, VP24 (Figure 1-3) 
(Brown, McVoy et al. 2002, Baines and Weller 2005, Conway and Homa 2011). The 
steps  of  this  process  are  unclear  and  will likely remain so in the absence of an in  
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Figure 1-3 The proposed model for HSV-1 DNA packaging. 
During viral genome packaging, UL15, UL28 and UL33 form a 
terminase complex that binds viral DNA and docks with the viral 
portal (yellow). DNA is driven into the capsid, most likely through the 
portal in an ATP-driven process. At this time, the internal scaffold is 
cleaved and expelled from the capsid, resulting in angularization of 
the capsid. The accessory proteins UL17 and UL25 bind to the 
capsid to aid in retention of the viral genome within the capsid. 
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vitro packaging system. Capsids can have one of three fates during this stage, 
becoming A-, B- or C-capsids. The separate capsid types are distinguished based 
on where they band on a sucrose gradient. A-capsids have the lowest mass and 
migrate toward the top of the gradient. These capsids are devoid of viral DNA and 
the internal scaffold, suggestive of capsids that were able to begin the packaging 
reaction but unable to retain the genome. B-capsids migrate in the middle due to the 
presence of the internal scaffold and are presumed to be dead-end products that 
never initiated packaging. C-capsids migrate the farthest down a gradient and have 
successfully packaged a full-length genome.  
Seven essential proteins form the components required for the formation of 
C-capsids: the UL6 portal protein, a terminase complex containing UL15, UL28 and 
UL33, UL25 and UL15 which form a capsid-vertex specific complex (CVSC) and the 
putative chaperone protein UL32. The terminase complex recognizes viral DNA, 
docks with the portal protein and drives the DNA into the capsid in an ATP-
dependent manner (Yu and Weller 1998, Yu and Weller 1998, Dasgupta and Wilson 
1999, Adelman, Salmon et al. 2001, Beard, Taus et al. 2002, Yang, Homa et al. 
2007, Higgs, Preston et al. 2008). The CVSC associates with the pentons and may 
play a role in the retention of the viral DNA after packaging. Mutants lacking UL25 
can still cleave viral DNA, however there is an accumulation of A-capsids, 
suggesting that DNA had been packaged but could not be retained within the capsid 
(McNab, Desai et al. 1998). It is interesting to note that although UL25 and UL17 
interact to form the CVSC, the UL17-null virus does not cleave viral DNA and these 
mutants produce B-capsids (Salmon, Cunningham et al. 1998). UL32 is the only 
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packaging protein that has not been found associated with the capsid. Its function in 
DNA encapsidation has been a mystery, however our lab previously described UL32 
as a chaperone responsible for the proper localization of the major capsid protein 
VP5 into replication compartments (Lamberti and Weller 1998). Work presented in 
this thesis describes a novel role for UL32. In Chapter 3, we present evidence that 
UL32 influences disulfide bond formation within several viral proteins, including the 
protease, VP24, and UL6 (Albright, Kosinski et al. 2015). Although we have 
observed that disulfide bonds are important for the formation and stability of the 
portal, these exciting results suggest that disulfide bonds may also be important for 
other essential processes, such as the activation of VP24.  
DNA packaging relies on the presence of motifs within the a sequence of the 
genome that serve as substrates for recognition and cleavage by the terminase. For 
instance, UL28 has been shown to bind specifically to the Pac 1 site within direct 
repeat elements at the UL terminus (DR1, Fig. 1-1) (Adelman, Salmon et al. 2001). 
Thus, packaging would begin at this end of the genome and stop when the 
terminase recognizes a Pac 2 site in the proper orientation, which would be at the 
US terminus (Vlazny, Kwong et al. 1982). This mechanism ensures that one 
complete copy of the genome is inserted into the capsid. During packaging, the 
scaffold is expelled and the capsid angularizes. When packaged, the DNA is 
compacted to an almost liquid-crystalline state with internal pressure of the capsid 
reaching up to ~ 18 atmospheres (Bauer, Huffman et al. 2013). This internal 
pressure most likely serves a role in the ejection of the viral genome during a 
subsequent round of infection. 
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Egress 
Packaged capsids face several barriers before final release into the 
extracellular environment. They have to exit the nucleus, transverse the cytoplasm 
and finally bud from the plasma membrane, all while acquiring an envelope and a 
layer of tegument. Exit from the nucleus is a difficult task due to the presence of the 
nuclear lamina, which is a meshwork of many proteins and serves as the internal 
framework of the inner nuclear membrane (INM). Two viral proteins, UL31 and 
UL34, form a heterodimer called the nuclear egress complex (NEC) which is 
essential for the initial budding event through the INM (Reynolds, Ryckman et al. 
2001). This event is also dependent on the viral kinase UL13 and US3 and the 
cellular atypical PKCs which phosphorylate nuclear lamins, thus disrupting this 
barrier (Leach and Roller 2010). The primary envelopment is followed by de-
envelopment via fusion with the outer nuclear membrane which was shown to be 
dependent on gB and gH/gL, the same glycoproteins needed for the entry of the 
virus (Connolly, Jackson et al. 2011). The naked capsid goes through a secondary 
envelopment, possibly through the trans-Golgi network, where it acquires its 
tegument as well as a double-membrane envelope such that it is essentially an 
enveloped virus within a vesicle (Turcotte, Letellier et al. 2005, Sugimoto, Uema et 
al. 2008). This outer membrane fuses with the plasma membrane, releasing the 
enveloped virion into the extracellular environment.  
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HSV-1 manipulates cellular stress pathways 
HSV-1 infection induces a robust cellular response. Throughout evolutionary 
time, the genes of the virus and host have been shaped to counteract each other. 
The virus may have picked up genes that were originally useless, but conferred a 
selective advantage somewhere along the timeline. Conversely, cellular pathways 
may have originally evolved to be antiviral but provided an advantage thus being 
fixed in the host. For instance, upon entry into the nucleus, the nicked and gapped 
viral genome encounters restrictive factors, such as PML bodies that localize to, and 
silence, the incoming genome. The virus has evolved a mechanism (ICP0 – 
mediated degradation) to disrupt this response. These measures and 
countermeasures are pretty obvious; a restrictive factor evolves, and the virus gets 
around it.  
HSV hijacks the host-cell protein quality control machinery (PQC), including a 
number of heat shock proteins (HSP) and the proteasome system (Burch and Weller 
2004, Livingston, DeLuca et al. 2008, Livingston, Ifrim et al. 2009, Bastian, 
Livingston et al. 2010, Weller 2010). We have found that individual components of 
the PQC are important for infection.  For instance, treatment with the Hsp90 
inhibitor, geldanamycin, prevents the localization of the viral polymerase to the 
nucleus and thus inhibits growth (Burch and Weller 2005). Also, viral growth is 
somewhat attenuated (< 1 log) when infecting cells transiently express a 
dominant/negative Hsc70 (Li, Johnson et al. 2008).  However, the dependence on 
these heat shock proteins for efficient viral infection does not explain how and why 
they are sequestered in VICE domains. VICE domains are localized on the periphery 
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of replication compartments. Does the virus use these sites for assembling or 
remodeling viral protein complexes, or is the virus actively degrading proteins? If so, 
what are these proteins and why? Alternatively, could sequestration prevent PQC 
proteins from executing yet unknown antiviral functions?  
It is known that the transcription factor responsible for upregulating cellular 
chaperones (heat shock factor 1, HSF-1) is modified during infection, and preventing 
its phosphorylation is detrimental to the virus (Livingston, et al, unpublished). We 
have been interested in how and why it gets modified, as well as what the exact 
modifications are. There are a few possibilities that could explain this modification: 1) 
viral kinases could possibly phosphorylate HSF-1, 2) viral infection could prevent 
phosphatases from dephosphorylating HSF-1 shifting the predominant species to 
the active form or 3) the intracellular environment could be altered in a way that 
would activate HSF-1. These aren’t mutually exclusive and it is possible that a 
combination of factors could elicit a stress response. Thus, it seems that this stress-
response pathway plays a vital role in HSV infection and deserves further 
investigation. In the next few sections, and later in the thesis, we will discuss how 
HSV does in fact alter the cellular milieu and how these changes might be important.  
 
Viruses and ROS  
The relationship between ROS and microbial infection is a topic of intense 
investigation. The severity of disease caused by many infections is directly 
correlated with ROS levels due to direct damage of macromolecules as well as 
ROS-induced inflammation (Lin, Liu et al. 2000, Imai, Kuba et al. 2008, Seet, Lee et 
	  	  24	  
al. 2009, Ibeh and Emeka-Nwabunnia 2012, Ivanov, Bartosch et al. 2013, Lee, Lai et 
al. 2013, Paracha, Fatima et al. 2013, Olagnier, Peri et al. 2014, Soundravally, Hoti 
et al. 2014). Although this response would be presumed to clear pathogens, a 
remarkable number of viruses are not only able to tolerate, but to thrive in a pro-
oxidant environment. Recent work suggests that 1) virus production is more efficient 
in the presence of oxidants (Paiva and Bozza 2014) and 2) these viruses are 
sensitive to antioxidant treatment (references listed below). Here I will highlight a few 
of the viruses in which the induction and role of ROS is well studied. This is not a 
comprehensive review; however, extensive reviews on this topic can be found 
elsewhere (Fraternale, Paoletti et al. 2009, Campagna and Rivas 2010, Bottero, 
Chakraborty et al. 2013, Paiva and Bozza 2014). Before I discuss the viruses, it is 
important to understand what ROS are. 
 
 
Reactive oxygen species 
Reactive oxygen species (ROS) are the partially reduced metabolites of 
molecular oxygen and are known for their ability to cause damage to most cellular 
macromolecules. These species include peroxides (i.e. H2O2), superoxide anions 
(O
−2 ) and hydroxyl radicals (OH.). Although ROS are generally thought to be 
deleterious, they are being recognized as essential signaling molecules involved in 
regulating cellular processes, such as cell proliferation, cell death and gene 
transcription (Sauer, Wartenberg et al. 2001, Valencia and Moran 2004, Collins, 
Chouchani et al. 2012). They also serve as an important host defense against 
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microbial pathogens; phagocytic cells generate oxidative bursts for pathogen 
clearance and stimulate the inflammatory response (Iles and Forman 2002). Thus 
ROS are  necessary but must be kept in check.  
Not all ROS exhibit the same reactivities, and the three species that will be 
discussed follow the hierarchy H2O2 < O2- < OH.. H2O2 is the most stable ROS and is 
membrane permeable, making it of significant interest as a potential signaling 
molecule. By itself, H2O2 is a poor oxidant, but can react with Fe through Fenton 
chemistry to form the extremely reactive OH. radical, which is the suggested 
mechanism for why H2O2 is toxic (Luo, Han et al. 1994). The predominant cellular 
buffer against ROS is the small tripeptide glutathione (GSH) that exists in cells at an 
estimated 1-10 mM concentration. An important characteristic of GSH is the 
presence of a thiol group on the molecule, which can serve as an antioxidant by 
directly reacting with ROS. GSH can also form adducts with free thiols on other 
proteins to protect them from being oxidized (Lushchak 2012). The properties of the 
thiol groups, as well as the high concentration, make GSH the most important 
antioxidant defense mechanism for the cell. The cell has many other mechanisms to 
maintain homeostatic levels of ROS comprised of other antioxidant molecules 
(vitamin C, vitamin E, etc.) and enzymes (catalase, superoxide dismutase (SOD), 
etc.).  
 
Endogenous Sources of ROS  
It has been difficult to study ROS in vivo due to a lack of specific probes. For 
instance, most studies use redox-sensitive fluorescent dyes, but these can have 
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different selectivities to different reactive oxygen species or, even worse, react with 
other cellular components, such as cytochrome c, which can influence the 
interpretation of the results (Wardman 2007). The design of better molecular tools to 
study these volatile systems in vitro and in vivo has led to a rapid expansion in the 
field of redox biology. Although it is important to understand how ROS influence 
cellular processes, it is equally important to understand where these ROS come 
from. There are many exogenous sources of ROS, from xenobiotics to ultra-violet 
radiation, however we will limit our discussion to the endogenous species. 
 
Mitochondrial sources of ROS 
During cellular respiration, a series of transmembrane enzymes in the inner 
mitochondrial membrane participate in an electron transfer relay known as the 
“electron transport chain” (Fig 1-4). Each relay provides the energy to actively pump 
protons into the intermembrane space, resulting in an electrochemical gradient. The 
protons re-enter the inner membrane through the ATP-synthase enzyme (complex 
V), thus acting as the driving force for ATP synthesis. This event, known as oxidative 
phosphorylation, is essential for providing energy for the cell, but it can also 
generate ROS in the process. O2 serves as the final electron acceptor at the end of 
the chain (complex IV) where it gets converted to water. Premature leakage of 
electrons from complexes I and III in the chain can result in partial, or incomplete, 
reduction of O2 leading to the formation of O2-. Unlike other mitochondrial ROS 
generators, complex III releases O2- into both the matrix and the intermembrane 
space and thus is the most likely source of mitochondrial ROS   that  leaks  into   the 
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Fig.1-4 Model of mitochondrial ROS generation. During cellular respiration, electrons are transferred 
from NADH and FADH2 to complexes I and II in the electron transport chain. Oxygen (O2) serves as the 
final electron acceptor and is  ultimately reduced to form water at complex IV. Mitochondrial ROS are gener-
ated from the leakage of electrons to form superoxide at complex I and complex III. Superoxide is produced 
within the matrix at complex I; whereas, at complex III superoxide is released towards both the matrix and 
the intermembrane space. Once generated, superoxide is dismutated to hydrogen peroxide by superoxide 
dismutase 1 (SOD1) or SOD2. This is followed by  reduction to water by glutathione peroxidase (GPX). 
Both superoxide and hydrogen peroxide are produced in this process. 
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cytoplasm (Brand 2010). These ROS are easily handled by the many antioxidant 
systems in the mitochondria. It was initially thought that this accidental ROS 
generation was one of the major contributors to intracellular ROS, however, this idea 
is falling out of favor as the studies that show this were either done in vitro with 
purified mitochondria or with drugs that may skew the results (Brand 2010, Sena and 
Chandel 2012). Thus, there is still no real evidence that mitochondria contribute 
substantially to the intracellular ROS pool in vivo under normal physiological 
conditions. Even under pathological conditions where mitochondrial dysfunction 
increases cellular ROS, the observed ROS is generated by another set of enzymes 
called the NADPH-oxidases (NOXs) which are being recognized as possibly the 
biggest contributors of intracellular ROS (Bedard and Krause 2007, Jiang, Zhang et 
al. 2011, Bauer, Huffman et al. 2013). 
 
NADPH – oxidases and ROS      
The NOXs are a family of conserved transmembrane proteins that are the 
major source of intentional ROS generation. There are seven NOXs that have been 
identified and they all display unique tissue and cellular distribution. NOX2, the first 
NOX identified and the most well studied, is expressed in macrophages and NK cells 
and produces a robust oxidative burst essential for pathogen clearance (Bedard and 
Krause 2007). The other NOXs (1,3-5 and Duox 1,2) are less well studied and their 
roles under normal physiological conditions aren’t known. Unlike mitochondria, 
NOXs can provide an immediate oxidative burst that can be shut off making it a 
more tightly regulated redox signaling system, possibly as a stress response (Jiang, 
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Zhang et al. 2011). Another possibility is that these enzymes provide a respiratory 
burst, as in NOX2, to protect the cells from pathogens. This might not be the case 
with NOX4 which, unlike the other NOXs, generates H2O2 instead of O
−2  (Martyn, 
Frederick et al. 2006), suggesting that it may serve a unique signaling role.  
 
Influenza and ROS 
The relationship between influenza viruses and ROS has long been 
recognized. It was originally observed that ROS contribute to the pathogenesis of 
the virus (Akaike, Ando et al. 1990, Hennet, Peterhans et al. 1992, Peterhans 1997), 
and subsequent studies showed that antioxidant treatment attenuates viral growth in 
cell culture and animal models (Cai, Chen et al. 2003, Nencioni, Iuvara et al. 2003).  
Defective viral growth in cell culture seems in part due to improper maturation of the 
HA glycoprotein (Nencioni, Iuvara et al. 2003, Sgarbanti, Nencioni et al. 2011). The 
reasons for the attenuated growth in mouse models aren’t entirely clear, but it is 
apparent that ROS are important for the growth of the virus. This is further supported 
by the observation that influenza growth is restricted in NOX2 knockout mice, or 
mice treated with the NOX2 inhibitor, apocynin (Vlahos, Stambas et al. 2011) 
suggesting that NOX2-induced ROS is required for efficient infection in animals. 
Surprisingly, a recent study shows that NOX4 and not NOX2 is important for 
influenza infection in lung epithelial cells (Amatore, Sgarbanti et al. 2015). The 
authors show that abrogating NOX4 activity, through shRNA knockdown or by using 
chemical inhibitors, prevents influenza-induced ROS and reduces viral growth. 
Furthermore, blocking NOX-4 mediated ROS generation results in inhibition of 
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MAPK signaling and accumulation of the viral ribonucleoprotein (vRNP) in the 
nucleus. This is especially interesting as a new study confirmed that caspase 
activation results in enlargement of the nuclear pores which is required for exit of the 
vRNPs from the nucleus (Muhlbauer, Dzieciolowski et al. 2015). Thus the work by 
Amatore, et al, suggests that NOX4-induced ROS might be responsible for caspase 
activation through MAPK signaling. It will be interesting to see if NOX4 is essential 
for influenza infection in mice. 
 
HIV and ROS 
 Early studies on human immunodeficiency virus (HIV) revealed that oxidative 
stress (OS) played some role in disease. The first evidence was the accumulation of 
lipid peroxidation markers and depletion of the antioxidant GSH in serum samples of 
patients (Sonnerborg, Carlin et al. 1988, Droge, Eck et al. 1994, Favier, Sappey et 
al. 1994, Perl and Banki 2000).  Although these markers of OS were seen even in 
asymptomatic patients (Buhl, Jaffe et al. 1989), it became apparent that OS directly 
correlated with the progression of the disease (Baruchel and Wainberg 1992, Droge, 
Eck et al. 1994, Perl and Banki 2000). The observation that ROS induce viral gene 
transcription by activating the transcription factor NF-kB, which could be prevented 
by antioxidant treatment, provided clues to how OS was involved in the 
pathogenesis of HIV (Nabel and Baltimore 1987, Staal, Roederer et al. 1990).  One 
way the virus induces OS is by downregulating key antioxidant enzymes (Masutani, 
Naito et al. 1992, Flores, Marecki et al. 1993). For instance, superoxide dismutase 
expression is downregulated by the viral protein, Tat (Flores, Marecki et al. 1993) 
	  	  31	  
which reduces the cells ability to buffer against ROS. This is especially important 
since the HIV protease has been shown to cleave a protein responsible for the 
integrity of the mitochondrial membrane, Bcl-2 (Strack, Frey et al. 1996). 
Interestingly, a more recent study showed that Tat-induced ROS is mediated 
through NOX2 (Song, Ju et al. 2011). The viral proteins gp120 and VPR have also 
been shown to induce OS (Price, Ercal et al. 2005, Deshmane, Mukerjee et al. 
2009). OS results in the constitutive release of TNF-α, which has been implicated in 
persistent activation of the immune response during HIV infection.  This has been 
linked to the depletion of CD4+ cells which contributes to the onset of AIDS (Aukrust, 
Liabakk et al. 1995). The role of OS in this capacity is still murky; however, there is 
compelling evidence that OS is associated with HIV-induced neurodegeneration.  
 
HSV-1 and ROS  
The relationship between HSV-1 and ROS has been recognized since 1995 
when it was observed that GSH levels were decreased in cells immediately after 
infection and that exogenous GSH treatment was deleterious for viral growth 
(Palamara, Perno et al. 1995). These studies were confirmed in rabbits (Nucci, 
Palamara et al. 2000) and mice (Vogel, Cinatl et al. 2005)  using derivatives of GSH, 
suggesting that HSV requires a pro-oxidant state in cell culture and in live animal 
models. This is consistent with the accumulation of ROS in HSV infected cells, as 
detected with redox-sensitive fluorescent dyes (Kavouras, Prandovszky et al. 2007, 
Aubert, Chen et al. 2008, Schachtele, Hu et al. 2010, Hu, Sheng et al. 2011, 
Gonzalez-Dosal, Horan et al. 2012). Furthermore, protein carbonylation and lipid 
	  	  32	  
peroxidation have been observed during infection, suggesting that the cells are 
undergoing severe OS (Kavouras, Prandovszky et al. 2007, Mathew, Bryant et al. 
2010).  
The role of OS during HSV infection is entirely unclear. Early work suggested 
that GSH blocks HSV growth at a late stage of the infection cycle and was likely due 
to a defect in expression or maturation of the viral glycoprotein, gB (Palamara, Perno 
et al. 1995). This has been the only mechanism proposed to explain why HSV needs 
a more oxidizing environment. In work presented in this thesis, I observed that there 
was a defect in viral protein expression, viral replication compartment formation and 
viral growth even at early times post infection in the presence of GSH (Chapter 4), 
suggesting that OS could play a role in infection much earlier than originally 
believed. Interestingly, there have been multiple observations that stress-related 
proteins, such as Jnk, p38 MAPK, ERK, NF-kB and HSF-1, are phosphorylated (and 
presumably activated) during infection (Hargett, McLean et al. 2005, Schachtele, Hu 
et al. 2010, Livingston, et al unpublished, Hu, Sheng et al. 2011, Qiu, Chen et al. 
2013). The immediate early protein ICP27 has been implicated in activating several 
of these pathways (Hargett, McLean et al. 2005, Hargett, Rice et al. 2006, Salaun, 
MacDonald et al. 2010), which is especially intriguing since ICP27 has been known 
to induce ROS (Kim, Choi et al. 2008). ICP27, as mentioned above, plays an 
important role in late gene expression and it is exciting to speculate that this 
regulatory role might involve some of these stress-induced transcription factors; 
similar to the role played by NF-kB in HIV gene regulation (Nabel and Baltimore 
1987, Staal, Roederer et al. 1990). Could ROS be a driver of late gene regulation 
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through these pathways? It is apparent that we have a long way to go before 
questions like this get answered. There is little doubt that the development of better 
technologies and the growing recognition of the importance of ROS will lead to 
dramatic advances in our understanding of many biological processes.  
 
Objective of the study 
 
 The original focus of this work was to investigate the hypothesis that UL32 is 
a virally encoded chaperone involved in the regulation of disulfide bonds necessary 
for the assembly of encapsidation-competent virus.  The original aims of this project 
were as follows: 
 
Aim 1. Determine possible functions of UL32.   
 
Aim 2. Investigate the hypothesis that UL32 is involved in the regulation of 
disulfide bond formation in the scaffold and other viral proteins.   
 
Aim 3. Identify viral and cellular interacting partners for UL32. 
 
In Chapter 3, we provide evidence that UL32 may in fact serve as a redox-sensitive 
chaperone responsible for proper disulfide bond formation within viral capsid 
proteins. This exciting result, as well as our observations that disulfide bond 
formation is an important bonding interaction for HSV-1 proteins (Chapter1, 
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(Albright, Nellissery et al. 2011, Szczepaniak, Nellissery et al. 2011)), led us to 
change course by investigating the role of reactive oxygen species and oxidative 
stress during viral infection.  
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Chapter 2 
 
Disulfide Bond Formation in the HSV-1 UL6 Protein is Required for 
Portal Ring Formation and Genome Encapsidation 
 
Brandon S. Albright1, Jacob Nellissery1, Renata Szczepaniak, and Sandra K. Weller 
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Albright, B. S., J. Nellissery, R. Szczepaniak and S. K. Weller (2011). "Disulfide bond 
formation in the herpes simplex virus 1 UL6 protein is required for portal ring formation 
and genome encapsidation." J Virol 85(17): 8616-8624. 
 
Abstract 
The HSV-1 UL6 portal protein forms a 12-subunit ring structure at a unique capsid 
vertex which functions as a conduit for encapsidation of the viral genome. We have 
previously demonstrated that the leucine zipper region of UL6 is important for inter-
subunit interactions and stable ring formation. We now demonstrate that inter-subunit 
disulfide bonds exist between monomeric subunits and contribute to portal ring 
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formation and/or stability. Inter-subunit disulfide bonds were detected in purified portal 
rings by SDS-PAGE under non-reducing conditions. Furthermore, treatment of purified 
portal rings with dithiothreitol (DTT) resulted in the disruption of the rings, suggesting 
that disulfide bonds confer stability to this complex structure. The UL6 protein contains 
nine cysteines that were individually mutated to alanine. Two of these mutants, C166A 
and C254A, failed to complement a UL6 null mutant in a transient complementation 
assay. Furthermore, viral mutants bearing the C166A and C254A mutations failed to 
produce infectious progeny and were unable to cleave or package viral DNA. In cells 
infected with C166A or C254A B-capsids were produced which contained some UL6 
but at reduced levels compared to those seen in wild type capsids. In addition, C166A 
and C254A mutant proteins expressed in insect cells infected with recombinant 
baculovirus failed to form ring structures. Cysteines at positions 166 and 254 thus 
appear to be required for inter-subunit disulfide bond formation. Taken together, these 
results indicate that disulfide bond formation is required for portal ring formation and/or 
stability and for the production of procapsids that are capable of encapsidation.  
 
Introduction 
 The products of Herpes simplex virus type 1 (HSV-1) DNA replication are 
head to tail concatemers which are resolved into monomeric genomic units and 
packaged into a preformed capsid shell in the nucleus of the infected cell 
(reviewed in (Brown, McVoy et al. 2002, Baines and Weller 2005, Conway and 
Homa 2011)). The HSV-1 capsid shell is composed of the major capsid protein 
(VP5), two triplex proteins (VP19C and VP23) and VP26. Minor capsid proteins 
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include UL6, UL15, UL17, UL25, UL28 and UL33. The process of cleavage and 
DNA packaging requires the six minor capsid proteins as well as UL32, which is 
not found associated with capsids (Lamberti and Weller 1998, Brown, McVoy et al. 
2002, Baines and Weller 2005, Conway and Homa 2011).  
 HSV capsid formation and genome encapsidation are reminiscent of the 
double-stranded DNA bacteriophages in that a procapsid shell is preassembled 
around a scaffolding protein that is not present in the mature virion (Steven, Trus et 
al. 1997, Baker, Jiang et al. 2005, Steven, Heymann et al. 2005). Bacteriophage 
and herpesviruses share an important structural element, a dodecameric portal 
ring located at a unique capsid vertex (Newcomb, Juhas et al. 2001, Trus, Cheng 
et al. 2004, Cardone, Winkler et al. 2007, Chang, Schmid et al. 2007). During HSV 
genome encapsidation, the portal ring provides a docking site for the terminase, an 
ATP-driven molecular motor that facilitates the uptake of viral DNA (Yu and Weller 
1998, Sheaffer, Newcomb et al. 2001, White, Stow et al. 2003, Yang, Homa et al. 
2007). Terminase is responsible not only for viral DNA uptake but also for the 
specific cleavage of viral genomes such that a monomeric unit of viral DNA is 
packaged in each capsid (Koslowski, Shaver et al. 1997, Yu and Weller 1998, Yu 
and Weller 1998, Koslowski, Shaver et al. 1999, Adelman, Salmon et al. 2001, 
Beard, Taus et al. 2002, Przech, Yu et al. 2003, White, Stow et al. 2003, Yang and 
Baines 2006). 
UL6 becomes incorporated into nascent HSV-1 capsids mediated by 
interaction with the UL26.5 major scaffold protein (Newcomb, Thomsen et al. 2003, 
Newcomb, Homa et al. 2005, Singer, Newcomb et al. 2005, Huffman, Newcomb et 
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al. 2008). Procapsids can assemble in the absence of UL6 via an interaction 
between UL26.5 and VP5 (Newcomb, Homa et al. 2001); however, when UL6 is 
present at initiation of assembly, UL6-containing capsids are formed, suggesting 
that the portal is incorporated at a very early step in assembly (Newcomb, Homa et 
al. 2005). These results may also suggest that capsid assembly is regulated such 
that capsids lacking UL6 do not assemble efficiently in infected cells. UL6 is known 
to self assemble into a dodecameric ring in lysates from insect cells infected with 
recombinant UL6-expressing baculovirus (Newcomb, Juhas et al. 2001). 
Interestingly, three UL6 mutant proteins, L429E L436E and D-LZ, bearing 
mutations in the leucine zipper region are unable to produce rings and form 
polymorphic aggregates instead (Nellissery, Szczepaniak et al. 2007). Moreover, 
these mutant viruses assemble B-capsids that are defective for virus growth, 
cleavage and packaging of the genomes. Thus, the ability to form a dodecameric 
portal ring appears to be essential for the formation of a procapsid that is 
competent for encapsidation.  
In this paper we investigated another type of bonding interaction that 
contributes to ring formation and/or stability. UL6 portal rings from insect cells 
infected with recombinant baculovirus were disrupted when exposed to reducing 
agents. Although disulfide bonds have been reported previously between HSV-2 
capsid proteins (Zweig, Heilman et al. 1979) and in HSV-1 scaffold proteins (Yang, 
Yang et al. 2000), this is the first report of disulfide linkages in the portal ring. 
Mutational analysis of UL6 identified cysteines 166 and 254 as essential for 1) 
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intermolecular disulfide bond formation; 2) formation and/or stability of portal rings 
and 3) production of procapsids that are capable of encapsidation.  
Materials and Methods 
Viruses, cells, antibodies and other reagents. The KOS strain of Herpes 
simplex virus 1 (HSV-1) was used as the wild type virus and as the parental strain 
for the generation of recombinant viruses C166A and C254A. The UL6 null virus, 
hr74, contains an insertion of the E.coli lacZ gene under control of the HSV-1 ICP6 
promoter and was described previously (Lamberti and Weller 1996). African green 
monkey kidney fibroblast cells (Vero) were obtained from the ATCC and used to 
propagate the WT type virus. The UL6 complementing cell line, UL6-31 (Lamberti 
and Weller 1996, Nellissery, Szczepaniak et al. 2007), was used to propagate hr74, 
C166A and C254A recombinant viruses. Jay C. Brown (University of Virginia 
Health System) provided anti-UL6 monoclonal antibodies 1C9 and 4G9 (Burch and 
Weller 2004). N-Ethylmaleimide (NEM) was purchased from Sigma and dissolved 
in ethanol (0.5 M). 
Recombinant baculoviruses and protein expression.  Wild-type, C166A and 
C254A recombinant proteins were expressed in Sf9 insect cells and purified as 
described (Nellissery, Szczepaniak et al. 2007). Briefly, 3.2 X 108 insect cells were 
infected with recombinant baculoviruses a multiplicity of infection (MOI) of 5 plaque 
forming units (PFU) per cell incubated at 28°C for 48 h. Inclusion bodies containing 
UL6 were isolated and resuspended in 0.5 ml of arginine (1.0 M, pH 7.5), kept on 
ice for 15 min with occasional mixing and centrifuged at 30,000 x g in a Beckman 
TL-100 ultracentrifuge at 4°C for 15 min to remove insoluble UL6 as described in 
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(25). The supernatant containing solubilized UL6 protein was used in all 
subsequent experiments.  
Purification of UL6 rings.  UL6 rings were purified by sucrose gradient 
centrifugation. In short, the solubilized UL6 protein (0.25 ml) was loaded onto a 
10–30% sucrose gradient containing 1.0 M arginine and spun at 48,000 rpm for 18 
h at 4°C in a SW 55Ti rotor. Gradient fractions (250 µl each) were collected using a 
BIOCOMP Piston Gradient fraction collector, stored on ice and subjected to SDS-
PAGE.  UL6 was detected by silver staining as follows: the gel was fixed for 1 hour 
(two 30 min incubations) in a 30% ethanol and 10% acetic acid solution, washed 
twice in 20% ethanol (10 min each wash) followed by one 20 min wash with water. 
The gel was sensitized in 0.1% sodium thiosulfate for 1 min, briefly rinsed with 
water and incubated in cold 0.1% silver nitrate for 30 min at room temperature.. 
Silver nitrate solution was removed; the gel was washed twice in water (1 min each 
wash) and developed with 3% potassium bicarbonate and 0.05% formaldehyde. 
Once the protein bands were detected, staining was terminated by replacing the 
developing solution with 5% acetic acid solution for 10 min. 
Electron Microscopy. Purified rings in 1 M arginine were either untreated (control) 
or treated with 100 mM DTT followed by the addition of 50 mM sodium bisulfite to 
react with the free –SH groups. For EM analysis, treated and untreated ring 
samples were adsorbed onto formvar – carbon coated grids, stained with uranyl 
acetate and visualized in a Philips CM10 transmission electron microscope 
operating at 60 kV (52,000X magnification). Wild type and mutant rings were also 
analyzed by EM as previously described (Nellissery, Szczepaniak et al. 2007). 
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Capsid isolation. Confluent monolayers of Vero cells in T225 tissue culture flasks 
were infected with KOS wild type or mutant virus at 37°C. At 18-20 h post infection 
the medium was discarded, the monolayers were washed with PBS and the cells 
scraped into 20 ml of PBS. Cells were pelleted at 200 x g for 15 min in a Beckman 
S4750 rotor, and the pellet containing 4-5 x 107 cells was resuspended in 5 ml of 
20 mM Tris pH 7.6 buffer followed by addition of 5 ml of 2x lysis buffer (2% Triton, 
20 mM Tris pH 7.6, 1 M NaCl, 4 mM EDTA). Cell lysates were incubated on ice for 
30 min, treated with MgCl2 and DNase at final concentrations of 20 mM and 0.1 
mg/ml, respectively, for 15-20 min at 37ºC and briefly sonicated in a cup horn 
sonicator (three 20 sec bursts at 50% power) to reduce viscosity. Insoluble 
material was removed by centrifugation at 10,000 x g for 15 min in an Beckman 
F6X100 rotor. The supernatants containing intracellular capsids were spun through 
a 1.5 ml cushion of 30% (wt/vol) sucrose in TNE buffer at 71,000 x g for 1 h in an 
SW41 rotor. Pellets containing capsids were resuspended in 700 µl of TNE, briefly 
sonicated in a cup horn sonicator to break up clumps and layered over a 20-50% 
(wt/vol sucrose in TNE) continuous gradient. Gradients were centrifuged at 71,000 
x g for 1h in an SW41 rotor and fractionated using a BIOCOMP Piston Gradient 
fraction collector. Collected fractions (250 µl each) were stored at -80ºC for further 
analysis by SDS-PAGE and Western blotting. For capsids isolated in the presence 
of NEM, cell monolayers were incubated at 37ºC in DMEM containing 10 mM NEM 
for 10 min prior to harvesting. NEM at a final concentration of 10 mM was also 
added to all other buffers used during the process of capsid isolation. Total capsids 
were isolated as described above except that instead of sucrose gradient 
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centrifugation, capsids pelleted through a sucrose cushion were reconstituted in 
reducing or non-reducing SDS-PAGE loading buffer.  
Infected cell lysates. Infected cell lysates were prepared as follows: Vero cells in 
a 100-mm-diameter tissue culture dish (1 X 107 cells) were infected with wild type 
or mutant virus stocks at an MOI of 10 PFU per cell at 37ºC. Infected cells were 
incubated at 37ºC in DMEM containing 10 mM NEM for 10 min prior to harvesting 
by scraping with a rubber spatula at 14 h post infection. Cells were collected by 
centrifugation at 1,000 rpm for 10 min and rinsed twice with PBS containing 10 mM 
NEM. Cell pellets were resuspended in 1 ml of reducing or non-reducing SDS-
PAGE loading buffer as described below and subjected to SDS-PAGE.  
SDS-PAGE under reducing and non-reducing conditions.  Rings, capsids and 
cell extracts were prepared either in reducing SDS buffer (50 mM Tris pH 6.8, 10% 
glycerol, 2% SDS, 100 mM DTT, 5% (vol/vol) β-mercaptoethanol, 0.02% (wt/vol) 
bromophenol blue) or non-reducing SDS buffer (50 mM Tris pH 6.8, 10% glycerol, 
2% SDS, 20 mM NEM, 0.02% (wt/vol) bromophenol blue). Samples were heated at 
95ºC for 3 min, briefly sonicated and resolved on a Tris-Glycine gel cast according 
to instructions provided by Biorad. Gels were silver stained or subjected to 
Western blotting. 
Western blot analysis. Proteins were electro-transferred to PVDF membranes, 
blocked with 5% fat free milk in TBST (150 mM NaCl, 20 mM Tris pH 7.5, and 
0.1% Tween) and incubated with antibodies against VP5 or UL6. Monoclonal 
antibodies IC9 or 4G9 (anti-UL6) (Nellissery,	  Szczepaniak	  et	  al.	  2007) were used at 
a dilution of 1:10,000 or 3E8 (anti-VP5) (Blewett, Black et al. 1996) at a 1:2,000. 
	  	   43	  
Membranes were washed with TBST and incubated with secondary antibodies 
conjugated to either horseradish peroxidase or alkaline phosphatase, washed 
again with TBST and proteins were detected as described in the manufacturer’s 
protocol. 
Generation of cysteine substitution mutations. Substitution mutagenesis was 
carried out as described previously	   (Nellissery, Szczepaniak et al. 2007). 
Sequences of the oligonucleotides used for mutagenesis are available upon 
request. HSV-1 genomic DNA was used as the template in a two-step PCR-based 
mutagenesis protocol (Higuchi, Krummel et al. 1988). To generate the single and 
double cysteine substitutions the PCR product was gel purified and cloned into the 
pENTR vector of Gateway system (Invitrogen) and then moved to pDEST40 vector 
following manufacture’s protocol. The 166A and 254A mutations were moved to 
Gateway pDEST10 for transfer into recombinant baculovirus genomes as 
described (Nellissery, Szczepaniak et al. 2007).  All plasmids containing mutant 
versions of UL6 were subjected to DNA sequencing to confirm the presence of the 
desired mutations.   
Marker transfer. Monolayers of the UL6-31 cell line (60mm dishes at 70% 
confluence) were transfected with 1 µg mutant plasmid DNA and 1 µg hr74 virus 
DNA using the Lipofectamine Plus reagent (Invitrogen Corporation). Transfection 
was done in serum-free Dulbecco’s modified Eagle medium (DMEM) containing 
PLUS reagent (8 µl) and LIPOFECTAMINE reagent (12 µl) in a total volume of 250 
µl. Transfected cells were incubated in DMEM containing 5% fetal bovine serum 
for 24 h, and harvested along with the culture supernatant. Viral stocks were titered 
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on the UL6-31 cell line and replated at a suitable dilution to yield approximately 
100 plaques on a 10-cm dish. The dishes were overlaid with 2% methyl cellulose in 
DMEM, and recombinant plaques were identified by overlaying with methyl 
cellulose solution containing 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside 
(50!µg/ml) over-night. The parental hr74 plaques stain blue, while the 
recombinants that contain the mutant UL6 gene and hence have lost the lacZ gene 
are colorless. Colorless plaques were selected, and each mutant was plaque 
purified three times as described (Nellissery, Szczepaniak et al. 2007). The 
presence of the desired UL6 mutant was confirmed by sequence analysis following 
PCR amplification of the region spanning the deletion.   
Virus yield and plaque assays. Virus yields were determined by infecting Vero or 
UL6-31 cells at an MOI of 0.5 PFU/cell and samples were collected at 24 hours 
post infection. Serial dilutions were plated on the UL6-31 cell line, overlaid with 
methyl cellulose, incubated for 72 h, fixed in 4% formaldehyde, and stained with 
1% crystal violet solution. Viral plaques were counted by eye.  
Transient complementation assay. The transient complementation assay was 
carried out as described previously (Martinez, Shao et al. 1992). In brief, freshly 
trypsinized exponentially growing Vero cells were transfected with 1 µg of either 
empty plasmid, wild type or mutant plasmid. At 18 h post transfection, cells were 
superinfected with hr74 at an MOI of 3 PFU per cell. At 24 h post infection, 
progeny viruses were harvested and assayed on the UL6-31 cell line for total yield. 
The percent complementation was calculated by dividing the titer obtained for the 
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mutant plasmid with the titer of the WT plasmid and multiplying by 100. The 
background titers from the empty plasmid samples were subtracted.  
Immunofluorescence microscopy. Vero cells grown on cover slips (70% 
confluent) were transfected with 1 µg of plasmids bearing WT or mutant UL6 
genes; at 16 hours post transfection the cover slips were washed with PBS and 
cells fixed with 4% paraformaldehde, washed again with PBS, permeabilized with 
0.5% Triton X 100, and washed again with PBS. The cover slips were then 
incubated in 5% goat serum as blocking solution and treated with a 1:200 dilution 
of the 4G9 monoclonal antibody for 1 hr. The cover slips were washed again in 
PBS, and incubated with the secondary antibodies conjugated to AlexaFluor 488 
for 30 min. They were then washed and mounted on glass slides using glycerol-
gelatin. The slides were examined using a Carl Zeiss Axiovert A410 confocal 
microscope and images collected. The images were exported to Photoshop to 
generate the final figures.   
 
Results 
Purified UL6 rings are sensitive to reducing reagents 
The UL6 protein plays multiple roles during viral assembly and 
encapsidation, including ring formation, interaction with scaffold and VP5 to 
nucleate the assembly of the procapsid shell, docking of the terminase and acting 
as a conduit for the uptake of viral DNA into capsids (Patel and MacLean 1995, 
Lamberti and Weller 1996, Patel, Rixon et al. 1996, Yu and Weller 1998, Newcomb, 
Juhas et al. 2001, White, Stow et al. 2003, Trus, Cheng et al. 2004, Newcomb, 
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Homa et al. 2005, Cardone, Winkler et al. 2007, Chang, Schmid et al. 2007, 
Nellissery, Szczepaniak et al. 2007). It is also likely that the UL6 portal plays a role 
during subsequent infections. UL6 exists as a dodecameric ring and the forces that 
promote UL6-UL6 inter-subunit assembly are not well understood. In this paper we 
tested the hypothesis that disulfide bonds contribute to UL6 ring formation and 
proper UL6 function. First we wanted to determine if purified UL6 protein contains 
disulfide bonds. To test this, UL6 was expressed in insect cells infected with 
recombinant baculovirus expressing wild type protein as described previously 
(Nellissery, Szczepaniak et al. 2007). Portal rings were purified by sucrose 
gradient sedimentation as described in Materials and Methods. UL6-containing 
fractions were identified by SDS-PAGE followed by Western blot analysis using 
UL6 polyclonal antibody (data not shown). Purified UL6 rings were subjected to 
SDS-PAGE under reducing and non-reducing conditions (Fig. 2-1A). In the 
presence of DTT, the major UL6 band migrated at a position expected for a 
monomeric UL6 corresponding to a molecular weight of 74 kDa. On the other hand, 
under non-reducing conditions a slower migrating species was observed, with no 
visible monomer, indicating the presence of inter-subunit cross-links. The 
appearance of a slow-migrating, cross-linked species that can be reduced to the 
monomeric form suggests the presence of inter-subunit disulfide bonds. 
UL6 expressed in insect cells infected with recombinant baculovirus forms 
rings that can be observed by electron microscopy (Newcomb, Juhas et al. 2001, 
Nellissery, Szczepaniak et al. 2007). To address whether disulfide bonds 
contribute to ring stability, UL6 rings were treated with DTT followed by the addition  
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Untreated DTT Treated
Fig. 2-1  UL6 rings contain disulfide bonds and are destabilized in the presence of 
reducing agents. UL6 protein was expressed in insect cells and purified by sucrose gradient 
sedimentation as described in Materials and Methods.  A.  Fractions containing UL6 were 
processed for SDS-PAGE under non-reducing and reducing conditions.  Molecular weight 
markers are shown in the middle lane.  The gel was silver stained, and the position of molecu-
lar weight markers are shown on the left.  B. Electron micrographs show preparations of UL6 
either untreated (left panel) or treated with DTT to reduce disfulfide bonds followed by addition 
of sodium bisulfite to prevent free sulfydryl groups from reforming disulfide bonds (right panel). 
The scale bar in each panel corresponds to 100 nm.
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of sodium bisulfite to prevent free sulfhydryl groups from reforming disulfide bonds. 
Figure 2-1B shows that in the untreated samples, portal rings were readily 
detected; however, in the DTT-treated samples, portal rings were not detected. 
These results suggest that disulfide bonds contribute to ring stability.  
Disulfide bonds are observed in vivo 
 To determine whether disulfide bonds in the UL6 ring could also be detected 
in HSV-1-infected cells, cell lysates and capsids were harvested from infected cells 
at 24 hpi as described in Materials and Methods. Prior to harvest, N-
ethylmaleimide (NEM) was added to bind and block any free –SH groups. The 
addition of NEM prior to lysis ensures that any disulfide bonds that are detected 
are actually present in the infected cell proteins in vivo rather than forming once 
the cells are lysed and the extracts are exposed to an oxidizing environment. Total 
capsids were harvested as described in Materials and Methods and compared with 
crude cell lysates. Capsids and lysates were subjected to SDS-PAGE under 
reducing and non-reducing conditions (Fig. 2-2). A prominent band corresponding 
to a monomeric unit of UL6 was detected in capsids and lysates under reducing 
conditions (Fig. 2-2, lanes 3 and 4). Under non-reducing conditions, four slower 
migrating species (marked a-d) and monomeric UL6 were observed in capsids (Fig. 
2-2, lane 1). The proportion of material in bands a-d and monomeric UL6 varies 
somewhat from preparation to preparation (data not shown), although band b is 
generally the most prominent of the slower migrating bands.  The variability is likely 
caused by the labile nature of disulfide bonds. Cell lysates contain bands a and b, 
a weaker signal for band c, no visible band d and monomeric UL6 (Fig. 2-2, lane 2- 
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Fig. 2-2  UL6 protein exhibits disulfide linkages in vivo.  Total capsids and 
crude cell lysates from infected cells were isolated and subjected to SDS-PAGE 
under non-reducing (lanes 1 and 2) and reducing (lanes 3 and 4) conditions as 
described in Materials and Methods.  The slower migrating species are labeled 
a-d.  Band d is very faint in this figure but has reproducibly been seen in several 
experiments.  The position of monomeric UL6 is marked with an arrow.  
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2). Thus, UL6 protein appears to be linked through disulfide bonds in capsids and 
in cell lysates. The observation that even under non-reducing conditions, UL6 
monomer was detected indicates that not all of the subunits in the portal ring were 
cross-linked; however, since the amount of UL6 in various species is variable, it is 
not possible to quantify the proportion of cross-linked species in capsids and 
lysates 
Cysteines 166 and 254 are essential for viral infectivity 
 The predicted sequence of the HSV-1 UL6 gene reveals the presence of 
nine cysteines. UL6 genes from several alphaherpesviruses were analyzed using 
the Clustal W program (Thompson, Higgins et al. 1994) revealing that cysteines 
145, 166, 254, 283, 293 and 539 are conserved in HSV-1, HSV-2, VZV, PrV and 
EHV-1 (Fig. 2-3). To investigate which residues are important for the observed 
disulfide linkages in HSV-1 UL6, each cysteine was mutated to an alanine using 
site directed mutagenesis as described in Materials and Methods; in addition, one 
double mutant was made. C to A mutants were tested for their ability to 
complement the growth of the UL6-null virus, hr74. Vero cells were transfected 
with plasmids bearing the wild type or mutant UL6 genes and then infected with a 
UL6 null virus (hr74) at an MOI of 3 PFU/cell. After twenty-four hours, virus was 
harvested and viral titers were determined on the UL6 complementing cell line, 
UL6-31. Figure 2-4 shows that most of the substitution mutations were able to 
complement hr74 as well as the plasmid bearing the wild type gene. An additional 
substitution mutant C21A was also able  to  complement  hr74  at  wild  type  levels  
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Fig. 2-3. Cysteines 145, 166, 254, 283 293 and 539 are conserved in alphaherpesviruses. 
The position of all nine cysteines in HSV-1 UL6 are shown on the left.  Multiple sequence 
alignment of the portal proteins from human herpesvirus 1 (HHV-1, HSV-1) gp011, human 
herpesvirus 2 (HHV-2, HSV-1) gp08, human herpesvirus 3 (HHV-3, VZV) gp55, pseudorabies 
virus (SuHV-1) UL6 and equine herpesvirus 1 (EHV-1) orf56 reveal that cysteines 145, 166, 
254, 283, 293 and 539 are conserved.  The numbering reflects the HSV-1 sequence. The 
sequences were obtained from the NCBI viral genome database, accession numbers 
NC_001806, NC_001798, NC_001348, NC_006151, NC_001491, respectively. Alignments 
were performed using Clustal W (Thompson, Higgins et al. 1994). 
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Fig. 2-4 Cysteine to alanine substitutions at positions 145, 166 and 254 abolish comple-
mentation ability.   Alanine substitution mutations were made at each of the cysteine residues.  
A transient complementation assay was used to determine the ability of the substitution mutants 
to complement the null virus hr74.   Vero cells were transfected with plasmid DNAs bearing 
cysteine to alanine mutations and superinfected with hr74 virus, and the resulting progeny virus 
was titrated on UL6-31 cells. This experiment was repeated three times.  Error bars represent 
the standard deviation.
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(data not shown). Three substitutions, C145A, C166A and C254A, were unable to 
complement hr74.  
 The lack of complementation could indicate that cysteines C145, C166 and 
C254 are essential for UL6 function or, alternatively, that mutant proteins are 
globally or locally misfolded. In order to determine whether the non-complementing 
mutants were able to synthesize stable UL6 protein, lysates from transfected cells 
were subjected to SDS-PAGE and Western blotting. C166A and C254A were able 
to synthesize wild type levels of UL6; however C145A was not, suggesting this 
mutation may have caused misfolding leading to instability (Fig. 2-5A). Next, to 
determine whether the mutant proteins could localize appropriately to the nucleus, 
immunofluorescence microscopy using anti-UL6 antibody was performed on cells 
transfected with plasmids expressing wild type or mutant UL6 genes. Figure 2-5B 
shows that as previously reported (Patel, Rixon et al. 1996), wild type UL6 
localizes to the nucleus of transfected cells even in the absence of other viral 
proteins. Cells transfected with plasmids expressing C166A and C254A mutant 
proteins exhibited nuclear fluorescence similar to wild type; however, the C145A 
mutant protein signal was less intense and was detected only in the cytoplasm 
consistent with the Western blot data. This suggests that the C145 mutant protein 
may be globally misfolded and unable to adopt a conformation that can be 
recognized by the transport machinery.  
Marker transfer was used to introduce the C166A and C254A mutations into 
the HSV-1 genome as described in Materials and Methods. The global instability of 
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Fig. 2-5  Western blot and Immunofluorescence analysis of wild type and mutant versions 
of UL6.  A) Vero cells were transfected with plasmids expressing wild type or mutant UL6 
proteins.  LYsates were subjected to SDS-PAGE and blotted with anti-UL6 monoclonal antibody 
(1C9).  Actin was included as an internal loading control.  B) Immunofluorescence images of Vero 
cells transfected with WT, C166A,  C254A and C145A plasmids stained with the 4G9 monoclonal 
antibody. 
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the C145A mutant prevented analysis of cysteine 145 in the context of infection. In 
order to determine whether cysteines 166 and 254 are required for viral growth, a 
viral yield experiment was performed on Vero and UL6-31 cells. Table 1 shows 
that in Vero cells infected with C166A and C254A mutant viruses, only background 
levels of infectious virus was produced. C166A and C254A mutants grew to wild 
type levels on the UL6 complementing cell line, UL6-31, indicating that the defect 
in virus growth was due to a mutation in the UL6 gene.  
The C166A and C254A mutants produce B capsids that contain lower 
amounts of UL6 than wild type 
 We next tested whether the C166A and C254A viral mutants could produce 
portal-containing capsids. Vero cells were infected with wild type or mutant virus, 
and capsids were separated by sucrose gradient sedimentation.  Fractions from 
across the gradient were subjected to SDS-PAGE and probed with monoclonal 
anti-UL6 and anti-VP5 antibodies. Figure 2-6 shows that cells infected with wild 
type virus displayed the expected pattern of A-, B- and C-capsids and that UL6 
specifically associated with capsid peaks. In contrast, cells infected with C166A, 
C254A or the UL6 null virus (hr74) contained only B-capids suggesting that 
packaging is defective (Fig. 2-6). Furthermore, mutant UL6 protein exhibited a 
specific association with viral capsids and was not distributed throughout the 
gradient. In order to compare the levels of UL6 in mutant and wild type capsids, B-
capsids were recovered from sucrose gradients and analyzed by Western blotting 
with monoclonal anti-UL6 and anti-VP5 antibodies. Figure 2-7 shows serial 
dilutions of capsids isolated from cells infected with KOS, C166A or C254A. 
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Fig. 2-6 Substitution mutants C166A and C254A produce B- but not A- or C- capsids. Vero 
cells were infected with KOS (WT), hr74 (null), C166A or  C254A as described in Materials and 
Methods.  Infected cell lysates were subjected to sucrose density gradient sedimentation, and 
fractions (1, top; 24, bottom) were subjected to SDS-PAGE and immunoblot analysis. Blots were 
divided into strips and probed separately with anti-UL6 and anti-VP5 antibodies. The positions of A, 
B, and C capsids are shown. 
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Fig. 2-7  Capsids isolated from cells infected with C166A and C254 mutant viruses contain 
reduced amounts of the UL6 protein compared to wild type KOS.  B- capids isolated from cells 
infected with KOS or C166A or C254A were serially diluted (1:1, 1:2 and 1:4) and analyzed by Western 
blot analysis using anti-VP5 and anti-UL6 antibodies.  The images were quantified using Image J 
software, and results are expressed as a ratio of the relative intensities of the UL6 and VP5 protein 
bands.
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Roughly similar amounts of VP5 were present in wild-type and mutant B-capsids. 
On the other hand, UL6 was present in reduced amounts in capsids from the 
C166A or C254A mutant viruses. The relative ratio of UL6 to VP5 was quantified 
and indicates that mutant capsids contain less UL6 than wild type.   The reduced 
amounts of UL6 in mutant capsids could indicate that each capsid contains fewer 
than 12 molecules of UL6. Under this scenario, the ability of mutant UL6 protein to 
form aggregates may be sufficient to nucleate procapsid assembly resulting in 
capsids each with diminished levels of UL6. Alternatively, it is possible that portal 
rings are able to form very inefficiently in cells infected with C166A or C254A 
mutants resulting in a small number of capsids with an intact portal ring and a 
majority of capsids with none. Under this scenario, however, even if some capsids 
with an intact portal ring are produced, the absence of C-capsids indicates that 
packaging is defective in mutant infected cells. Additional experiments will be 
needed to determine the distribution of UL6 in capsids from mutant-infected cells. 
We can conclude, however, that cysteines 166 and 254 are essential for efficient 
portal ring formation and for the production of procapsids that are able to 
encapsidate viral genomes. 
 The production of only B-capsids by cysteine substitution mutant viruses 
indicates that DNA packaging is defective. To verify this, DNA was isolated from 
cells infected with wild type or mutant viruses, digested with BamH I and subjected 
to agarose gel electrophoresis and Southern blot hybridization. These experiments 
indicated that wild type and mutant viruses are able to synthesize similar amounts 
of viral DNA but that the terminal S and Q fragments indicative of cleavage were 
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detected only in wild type virus-infected cells (data not shown). Thus C166A and 
C256A mutants are capable of DNA synthesis and procapsid assembly; however, 
procapsids are defective for cleavage and packaging and production of infectious 
progeny.  
Cysteines 166 and 254 are necessary for disulfide bond formation  
 We next asked whether the C166 and C254 mutants displayed the same 
cross-linked protein bands seen in lysates and capsids from cells infected with wild 
type virus (Fig. 2-2). Vero cells were infected with KOS, C166A or C254A. After 
twenty-four hours, cells were treated with NEM, and total intracellular capsids were 
isolated and subjected to SDS-PAGE under reducing and non-reducing conditions 
as described in Materials and Method. While slower migrating bands were 
observed in wild type capsids under non-reducing conditions, no slower migrating 
bands were seen in mutant capsids under the same conditions (Fig. 2-8). This 
result implies that cysteines 166 and 254 play a direct role in the formation of the 
disulfide bonds detected in UL6 in KOS capsids. 
To investigate whether cysteines 166 and 254 are involved in ring formation, 
baculovirus recombinants bearing these mutations were constructed and used to 
infect insect cells. Solubilized UL6 was isolated from wild type and mutant-infected 
cells and subjected to sucrose gradient centrifugation. Wild type UL6 protein was 
able to form a ring structure that could be visualized by light scattering; however, 
no rings were observed in the expected position in gradients containing the mutant 
proteins (data not shown). Fractions sedimenting at the position of the wild type 
rings were collected and analyzed by electron microscopy (Fig. 2-9). 
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Fig. 2-8 Cysteines 166 and 254 are essential for the formation of the slower migrating 
species.  Total capsids were prepared from cells infected with KOS, C166A or C254A as 
described in Materials and Methods.  For KOS, total capsids include A, B and C capsids; 
however, the two mutants can only produce B capsids.  Monomeric UL6 is labeled with an 
arrow.
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Fig. 2-9 C166A and C254A mutant proteins do not form rings in vitro.  Electron micro-
graphs show purified preparations of mutant and wild type UL6 protein expressed in insect 
cells using a recombinant baculovirus expression system. The photographs show negatively 
stained rings with dark central channels in the WT and mutant proteins show amorphous 
particles of variable dimensions and without a distinct central channel. The scale bar in each 
panel corresponds to 100 nm.
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The mutant protein formed aggregates that exhibited variable dimensions and did 
not contain a distinct central channel. These data demonstrate that cysteines 166 
and 254 are necessary for ring formation and/or stability. 
Discussion 
 In this paper we report that UL6 participates in disulfide bonds that are 
essential for portal ring integrity and for the formation of procapsids that are 
competent for encapsidation of viral genomes. Slow migrating UL6 bands were 
observed in purified portal rings that were reduced to monomeric UL6 by the 
addition of reducing agents, indicating the presence of disulfide cross-links. Since 
no other viral proteins are expressed in this experiment, it is likely that the slow 
migrating bands represent inter-subunit disulfide bonds; however, we cannot rule 
out the possibility that some slow migrating bands result from interactions of UL6 
with cellular proteins such as chaperones. The observations that portal rings did 
not form in insect cells expressing cysteine substitution mutations (C166A and 
C254A) and that portal rings were destabilized in the presence of reducing agents 
are consistent with the suggestion that inter-subunit disulfide bonds are present. 
Slow migrating species of UL6 were also seen in cell lysates and capsids from 
cells infected with wild type HSV but not in cells infected with mutants C166A and 
C254A suggesting that these two cysteine residues are required for the disulfide 
linkages. Mutant C145A was misfolded, and thus we cannot rule out that this 
residue also participates in disulfide bond formation. The inability of C166A and 
C254A to produce infectious virus and to package DNA is consistent with disulfide 
bond formation being essential for the production of procapsids that are competent 
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for cleavage and packaging. Although it is likely that some of the slow-migrating 
species seen in cell lysates and capsids (Figs. 2-2 and 2-8) represent inter-subunit 
interactions within the portal ring, it is also possible that some represent 
interactions between UL6 and other viral capsid proteins. We are intrigued by the 
possibility that during capsid formation, encapsidation and the production of mature 
virus, the disulfide bond profile is dynamic. For instance, it is possible that inter-
subunit disulfide bonds play a role in ring formation and that later during capsid 
assembly some bonds shift such that interactions between UL6 and other capsid 
proteins form to stabilize the capsid. In fact, some differences were observed in the 
pattern of slow migrating bands between B- and C- capsids and virions 
(unpublished results). Further experiments will be required to test this hypothesis 
and to identify relevant protein-protein interactions in this pathway.  
Interestingly, although mutant C166A and C254A proteins cannot form 
portal rings, they form aggregates when expressed in insect cells. In cells infected 
with mutant viruses, B-capsids were observed which on average contained UL6 in 
lower amounts than seen in wild type B-capsids. This behavior is reminiscent of 
our previous analysis of mutations in the leucine zipper region. UL6 protein 
expressed in insect cells infected with recombinant baculoviruses bearing 
mutations in this region were unable to form rings; instead, L429E L436E and D-LZ 
formed polymorphic aggregates. When studied in the context of viral infection, 
leucine zipper mutants as well as C166A and C254A assemble B-capsids that 
contain lower amounts of UL6 than seen in wild type and are not capable of 
encapsidation (Nellissery, Szczepaniak et al. 2007) and this paper). This may 
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indicate that it is not necessary to form a complete portal ring for procapsid 
assembly to occur and that aggregates of UL6 are able to interact with scaffold 
protein to initiate procapsid assembly. Alternatively, it is possible that a small 
minority of the B-capsids seen in the mutant-infected cells contain a complete 
dodecameric ring and that the majority of procapsids contain little or no UL6. Thus 
ring formation may be extremely inefficient but the few rings that can form may 
nucleate procapsid formation resulting in a small number of UL6-containing 
procapsids. Experiments are in progress to distinguish between these alternative 
explanations. It is also possible that in the B-capsids from mutant infected cells, 
UL6 is not found at a unique vertex. In any case it is clear that ring formation 
and/or stability is inefficient in both leucine zipper and the cysteine substitution 
mutants. Furthermore, the addition of reducing agents to portal rings resulted in 
disruption of the ring structure. Taken together, these results suggest that portal 
ring formation and/or stability requires at least two types of inter-subunit 
interactions driven by disulfide bond formation and coiled-coil interactions typical of 
leucine zippers. It will be important to understand the assembly principles of this 
interesting structure because an intact portal appears to be essential for all 
subsequent steps of capsid maturation. Portal assembly also provides a novel 
potential target for antiviral intervention. 
We report that slower migrating bands of UL6 were observed in capsids 
isolated from cells that had been pretreated with NEM. The presence of NEM 
prevents formation of disulfide bonds that could occur upon cell lysis and exposure 
to oxidizing conditions. This result implies that the disulfide bonds in these capsids 
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have already formed at the time of lysis. This may be surprising since the nucleus 
is generally assumed to be a reducing environment (Go and Jones 2008, Jones 
and Go 2010, Kietzmann 2010). It is possible that the assembly pathway of the 
UL6 portal occurs in a microenvironment in the nucleus that allows disulfide bond 
formation. Several observations suggest that the conformation of UL6 may be 
regulated in infected cells and that the formation of portal rings may take place in 
an unusual environment. In infected cells, most of the UL6 has been reported to 
localize to replication compartments where procapsid assembly is believed to 
occur; however, we have reported that a subpopulation of UL6 could be observed 
in Virus Induced Chaperone Enriched (VICE) domains which form adjacent to 
replication compartments during the earliest stages of HSV-1 infection (Burch and 
Weller 2004, Livingston, Ifrim et al. 2009). VICE domains contain several 
components of the host protein quality control machinery including molecular 
chaperones (e.g. Hsc70, the 20S proteasome and ubiquitin) (Burch and Weller 
2004, Livingston, Ifrim et al. 2009). We have proposed that HSV-1 infection 
induces the formation of nuclear protein quality control centers to remodel or 
degrade aberrant nuclear proteins that would otherwise interfere with productive 
infection (Livingston, Ifrim et al. 2009). Chaperone proteins in VICE domains may 
function to aid in the assembly of multimeric complexes. It is of interest that FRAP 
analysis indicates that the association of Hsc70 with VICE domains is dynamic 
(Livingston, Ifrim et al. 2009), suggesting movement between VICE domains and 
replication compartments. It is possible that VICE domains provide a 
microenvironment conducive for disulfide bond formation and ring formation. 
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According to this scenario, rings assembled in VICE domains would then enter the 
replication compartments where they would nucleate procapsid assembly.  In any 
case, the presence of a sub population of UL6 in VICE domains suggests that its 
conformation is regulated by host cell chaperones.   
The observation that the portal ring uses disulfide bond formation for 
stability is interesting in light of previous observations that HSV capsids contain 
disulfide bonds potentially involving VP5, triplex and scaffold proteins (Zweig, 
Heilman et al. 1979, Yang, Yang et al. 2000). We have confirmed the existence of 
disulfide bonds in capsids and virions and have demonstrated that these bonds 
contribute to overall capsid stability (Szczepaniak et al, manuscript in preparation). 
Viral capsids are dynamic structures that must protect viral genomes during the 
extracellular state while maintaining the ability to disassemble and release viral 
genomes during the next round of infection. Disulfide bonds may have several 
advantages for the creation of metastable capsids. In papilloma- and polymoma 
viruses disulfide bonds have been shown to play an important role in the 
metastability of capsids (Hare and Chan 1968, Huang, Estes et al. 1972, Walter 
and Deppert 1975). It is known that redox states are regulated differently in the 
cytoplasm, the nucleus and the extracellular space (Go and Jones 2008, Jones 
and Go 2010, Kietzmann 2010). Once papilloma- and polymoma viruses enter the 
reducing environment of the cytoplasm, it appears that conformational changes 
occur which facilitate the uncoating and release of the viral genome in order to 
initiate infection. The observations that disulfide bonds are present in extracellular 
HSV capsids as well as in portal rings suggest a role for redox state during HSV 
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infection. Upon entry, capsids and tegument proteins are released into the 
cytoplasm where rearrangements are possible (Meckes and Wills 2007). Capsids 
are then transported on microtubules and dock at the nuclear pore where they 
release their genomes into the nucleus (Ojala, Sodeik et al. 2000) (Sodeik, 
Ebersold et al. 1997).	  
 In summary, we have now shown that inter-subunit interactions of the portal 
ring of HSV-1 requires at least two types of protein-protein interactions: coiled-coil 
interactions and disulfide bond formation. UL6 plays several known roles in 
infection including nucleation of procapsid assembly, docking of terminase, DNA 
encapsidation and genome release during the next round of infection. It will be of 
interest to determine the precise role of disulfide bond crosslinking in portal ring 
formation, capsid assembly and stabilization and genome release.  
 
 
 
  
	  	   68	  
TABLE 2-1. Growth of KOS, hr74, C166A, and C254A on Vero and UL6-31 cells 
 
 	  
 
 
Virus yields were determined by infecting Vero or UL6-31 cells at an MOI of 0.5 
PFU/cell and collecting samples 24 hr post infection. Viral titers were determined on 
the permissive UL6-31 cell line.  	  
 
 
 
 
 
 
  
Cell line 
Virus (PFU/ml) 
KOS hr74 C166A C254A 
Vero 1.9 × 108 1.6 × 103 4.5 × 102 1.2 × 103 
UL6-31 1.0 × 108 7.5 × 107 1.6 × 107 3.1 × 107 
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Chapter 3 
 
 
The putative HSV-1 chaperone protein UL32 modulates disulfide 
bond formation during infection. 
 
Brandon S. Albright, Athena Kosinski, Renata Szczepaniak, Elizabeth A. Cook, Nigel D. 
Stow, James F. Conway and Sandra K. Weller 
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Abstract 
During DNA encapsidation, HSV-1 procapsids are converted to DNA-containing 
capsids by a process involving activation of the viral protease, expulsion of the scaffold 
proteins and the uptake of viral DNA. Encapsidation requires six minor capsid proteins 
(UL6, UL15, UL17, UL25, UL28 and UL33) and one viral protein, UL32, not found 
associated with capsids. Although functions have been assigned to each of the minor 
capsid proteins, the role of UL32 in encapsidation has remained a mystery. Using an 
HSV-1 variant containing a functional HA-tagged UL32, we demonstrated that UL32 
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was synthesized with true late kinetics and that it exhibited a previously unrecognized 
localization pattern. At 6 - 9 h post infection (hpi), UL32 accumulated in viral replication 
compartments in the nucleus of the host cell while at 24 hpi it was additionally found in 
the cytoplasm. A newly generated UL32 null mutant was used to confirm that although 
B-capsids containing wild-type levels of capsid proteins were synthesized, these 
procapsids were unable to initiate the encapsidation process. Furthermore, we showed 
that UL32 is redox sensitive and identified two highly conserved oxidoreductase-like C-
X-X-C motifs that are essential for protein function. In addition, the disulfide bond 
profiles of the viral proteins UL6, UL25, VP19C and the viral protease, VP24, were 
altered in the absence of UL32, suggesting that UL32 may act to modulate disulfide 
bond formation during procapsid assembly and maturation.   
 
Importance 
Although functions have been assigned to six of the seven required packaging proteins 
of HSV, the role of UL32 in encapsidation has remained a mystery. UL32 is a cysteine-
rich viral protein that contains C-X-X-C motifs reminiscent of proteins that participate in 
the regulation of disulfide bond formation. We have previously demonstrated that 
disulfide bonds are required for the formation and stability of the viral capsids and are 
also important for the formation and stability of the UL6 portal ring. In this report, we 
demonstrate that the disulfide bond profiles of the viral proteins UL6, UL25, VP19C and 
the viral protease, VP24, are altered in cells infected with a newly isolated UL32 null 
mutant virus, suggesting that UL32 acts as a chaperone capable of modulating 
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disulfide bond formation. Furthermore, these results suggest that proper regulation of 
disulfide bonds is essential for initiating encapsidation. 
 
 
Introduction 
The products of Herpes simplex virus 1 (HSV-1) DNA replication are head-to-tail 
concatemers that are resolved into monomeric genomic units and packaged into a 
procapsid shell in the nucleus of the infected cell (reviewed in (Brown, McVoy et al. 
2002, Baines and Weller 2005, Conway and Homa 2011)). The procapsid is comprised 
of the major capsid protein (VP5), triplex proteins (VP19C and VP23) and a 
dodecameric UL6 portal ring. The	   precursor of the viral protease (UL26) and 
scaffolding protein (UL26.5) form a scaffold around which the capsid shell assembles 
(Homa and Brown 1997, Conway and Homa 2011). During DNA encapsidation, the 
viral protease (VP24) is activated, scaffold proteins are released and viral DNA is taken 
up (Homa and Brown 1997, Steven 1997, Brown, McVoy et al. 2002, Steven, Heymann 
et al. 2005, Preston, Murray et al. 2008). HSV procapsid maturation involves dramatic 
structural remodeling resulting in the conversion of a relatively fragile and porous 
procapsid into a more stable angular icosahedron filled with DNA (Steven 1997, Steven, 
Heymann et al. 2005, Roos, Radtke et al. 2009). Three types of capsids designated 
type A, B or C can be separated by sucrose gradient centrifugation. A-capsids have 
released the scaffold but contain no DNA as a result of an abortive packaging event. B-
capsids resemble procapsids in that they retain the scaffold and contain no DNA. C-
capsids contain viral genomes and are destined to mature into infectious virions. We 
have recently demonstrated disulfide linkages between capsid proteins VP5, VP23 and 
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VP19C and other components of the mature virion including UL17, UL25 and tegument 
proteins; furthermore, we showed that disulfide bond formation is required for capsid 
stability (Szczepaniak, Nellissery et al. 2011). Inter-subunit disulfide bonds also exist 
between monomeric subunits of the portal ring and contribute to ring formation and/or 
stability (Albright, Nellissery et al. 2011). The disulfide bonds in the portal ring can be 
detected in the nucleus. This result was somewhat surprising since this compartment is 
normally thought to be a reducing environment. 
 The cleavage and packaging machinery consists of several required viral gene 
products, six of which are transiently or stably associated with capsids. The UL6 portal 
ring is found at a unique vertex on the procapsid and acts as a channel through which 
DNA is taken up (Newcomb, Juhas et al. 2001, White, Stow et al. 2003, Trus, Cheng et 
al. 2004, Cardone, Winkler et al. 2007, Chang, Schmid et al. 2007). UL15, UL28 and 
UL33 make up a heterotrimeric complex believed to act as a molecular motor 
facilitating DNA uptake and cleavage known as the terminase (Yu and Weller 1998, 
Adelman, Salmon et al. 2001, Beard, Taus et al. 2002, White, Stow et al. 2003). 
Terminase subunits are transiently associated with procapsids (Yu and Weller 1998, 
Sheaffer, Newcomb et al. 2001, Beard, Duffy et al. 2004). UL17 and UL25 form a 
heterodimeric structure referred to as the Capsid Vertex Specific Component (CVSC) 
that appears to stabilize DNA-containing capsids (Ogasawara, Suzutani et al. 2001, 
Sheaffer, Newcomb et al. 2001, Thurlow, Rixon et al. 2005, Newcomb, Homa et al. 
2006, Thurlow, Murphy et al. 2006, Trus, Newcomb et al. 2007, Conway, Cockrell et al. 
2010). A seventh viral protein, UL32, is also essential for encapsidation; however, it is 
apparently not associated with procapsids or mature virions, and its precise role in 
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infection remains elusive (Lamberti and Weller 1998). UL32 also differs from the other 
cleavage and packaging proteins with respect to its intracellular localization. While 
other cleavage and packaging proteins are found in the nucleus in globular domains 
known as replication compartments, UL32 has been shown to localize primarily in the 
cytoplasm with a small fraction observed in replication compartments (Chang, Poon et 
al. 1996, Lamberti and Weller 1998). In the present study, an HSV-1 virus expressing 
HA-tagged UL32 was generated and used to demonstrate that UL32 localization is 
more dynamic than previously reported. At early times during infection UL32 localized 
predominantly within replication compartments; however, as infection progressed, 
UL32 was observed primarily in the cytoplasm. This dynamic staining pattern is unique 
among encapsidation proteins and may provide clues into the function of UL32. 
UL32 is a cysteine-rich protein, and fifteen of its twenty-two cysteines are 
conserved among the herpesviruses family. Cysteines contain a reactive thiol group 
that can be modified in response to changes in oxidation state. Interestingly, cysteines 
are involved in many cellular processes including redox signaling and dithiol-disulfide 
exchange reactions; furthermore, they play important roles at the catalytic site of many 
enzymes (reviewed in (Netto, de Oliveira et al. 2007)). UL32 contains three C-X-X-C 
motifs which are reminiscent of highly conserved motifs found in thiol-disulfide 
oxidoreductases known to catalyze redox reactions essential for maintaining the redox 
balance within cells through the formation and disruption of disulfide bonds in client 
proteins (Chivers, Laboissiere et al. 1996, Chivers, Prehoda et al. 1997, Fomenko and 
Gladyshev 2003, Becerra, Delaye et al. 2007). In this study, we tested the hypothesis 
that UL32 is a redox-sensitive protein involved in the modulation of disulfide bonds in 
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HSV-1 proteins. We show that UL32 is redox sensitive and that two of these three 
conserved C-X-X-C motifs are essential for protein function. Furthermore, the viral 
proteins UL6, UL25, VP19C and the viral protease, VP24, exhibit an altered disulfide 
bond pattern in cells infected with a UL32 null mutant supporting the hypothesis that 
UL32 functions either directly or indirectly to regulate disulfide bond formation. These 
results also suggest that appropriate disulfide bond formation is required for the 
formation of procapsids that are competent for encapsidation. 
 
Materials & Methods   
Cell lines and viruses. African green monkey kidney cells (Vero CC181; American 
Type Culture Collection, Rockville, MD) and the UL32-mutant virus complementing cell 
line, 158, were maintained and propagated in Dulbecco’s modified Eagle’s medium 
(Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum and 1% 
penicillin/streptomycin. The KOS strain of HSV-1 was used as the wild-type virus. The 
HSV-1 UL32 null mutant virus hr64 with an ICP6:LacZ insertion was previously 
described in Lamberti and Weller (1998). A replication competent virus, HA32, 
expressing an HA-tagged UL32 protein and a newly isolated true-null UL32 mutant, 
hr64FS, were generated in this study (see below). Cell maintenance and infections 
were carried out at 37°C.  
Construction of HA32. A plasmid (pUL32) capable of expressing the full length UL32 
ORF (pUL32) was kindly provided by Dr. A. Patel (CVR). PCR was used to insert a 
sequence encoding the influenza HA tag (YPYDVPDY) between codons 2 and 3 of the 
UL32 gene generating pHA-UL32. Plasmid pHA-UL32 and plasmid pUL33 (Beilstein, 
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Higgs et al. 2009) containing a fragment encoding the adjacent UL33 gene, were then 
used to generate p33-HA-32, in which a complete UL32-UL33 locus, identical to wt 
virus except for the sequence encoding the tag, was reconstructed. A fragment 
spanning the UL32-UL33 region was excised from p33-HA-32 and gel purified. 
Monolayers of BHK cells (seeded at 1X106 per 35 mm Petri dish) were transfected with 
0.5µg hr64 DNA and 0.5µg linearized plasmid using the calcium phosphate method as 
previously described (Stow and Wilkie 1976). Cells were incubated in GMEM media 
supplemented with 5% serum at 37ºC for three days. Serial two-fold dilutions were 
used to infect BHK cells in a 96-well plate and wells containing single plaques were 
identified and the resultant virus was analyzed for the ability to express HA32 by 
Western blot. One clone was selected and working stocks of the resulting virus, HA32, 
prepared. 
Construction of hr64FS. A UL32 mutant containing a frameshift deletion at nucleotide 
166 was generated by two-step sequential PCR mutagenesis using the following 
primers: Forward 5’-CAGTCACTGATAGGTGTGCCGCCCGTCGGTAC-3’ and 
Reverse 5’-CGGCACACCTATCAGTGACTGGCCGTCAGG-3’. This led to a site-
specific deletion of a single nucleotide (between the underlined nucleotides) and the 
presence of two consecutive in-frame stop codons (bold). The following primers were 
used to amplify the full-length product containing the frameshift mutation: Forward 5’-
CACCATGGCAACTTCGCCCCCCGGGGTCC-3’ and Reverse 5’-
TCATACATAGGTACACAGGGTGTGCTC-3’. The forward primer introduced a NcoI 
restriction site at the 5’ end of the UL32 gene. This PCR product was ligated into 
pUL32lacZ (Lamberti and Weller 1998) after digestion with NcoI and NheI to create 
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p32STOPlacZ. p32STOPlacZ was digested with NheI and XbaI and the fragment was 
inserted in place of NheI-XbaI fragment of p205-Pstl (Lamberti and Weller 1998), which 
contains genes UL31-UL33, resulting in p205-32STOP. Linearized p205-32STOP was 
co-transfected with infectious hr64 DNA into 158 cells at a molar ratio of 10:1. 
Infectious particles were harvested and used to infect 158 cells in a plaque assay, and 
blue-white screening with X-gal was utilized to select white plaques. 
Western blot analysis. Cells were harvested and proteins were separated by reducing 
SDS-PAGE as previously described and transferred to a PVDF membrane (Albright, 
Nellissery et al. 2011). Membranes were blocked with 5% milk and incubated overnight 
with the following antibodies: mouse monoclonal anti-HA (Santa Cruz Sc-7392) 
1:1,000; rabbit polyclonal anti HA (Clontech 631207) 1:1,000, rabbit polyclonal anti-
UL32 1:1,000 (generated by Open Biosystems to synthetic antigenic peptide); mouse 
monoclonal anti-ICP8 1:2,000 (abcam ab20194); mouse monoclonal anti-VP5 
(EastCoast Bio HA018) 1:1,000; mouse monoclonal anti-VP24 9-2 (Sheaffer, 
Newcomb et al. 2000) 1,000; mouse anti-Actin (Sigma A5441) 1:10,000.  
Growth curves. Confluent Vero or 158 cells were infected with the indicated viruses at 
an MOI of 0.1. Cells and supernatant were harvested at 0, 6, 12 and 24 hours post-
infection. After three freeze-thaw cycles, serial dilutions were plated on Vero cells (Fig. 
3-1) or 158 cells (Fig. 3-6), overlaid with methyl cellulose, incubated for 72 h, fixed in 
4% formaldehyde, and stained with 1% crystal violet solution. Viral plaques were 
counted by eye. 
Immunofluorescent confocal microscopy. Monolayers of Vero cells were grown on 
glass coverslips prior to infection. Infected cells were washed with 2X phosphate-
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buffered saline (PBS), fixed in 4% paraformaldehyde and permeabilized in ice cold 
acetone for 2 min followed by blocking in 3% normal goat serum (NGS) diluted in PBS. 
Cells were incubated in primary antibodies diluted in 3% NGS for 1-2 h at room 
temperature by inverting coverslips onto a drop of antibody dilution. Dilutions of primary 
antibodies in 3% NGS were as follows: monoclonal anti-ICP8 1:200; polyclonal anti-
ICP8 (367) 1:500; monoclonal anti-VP5 5C and monoclonal anti-VP23 1D2 (both 
generously provided by Jay Brown, University of Virginia) 1:200; monoclonal anti-
VP21/VP22a MCA406 (Serotec Inc.) 1:500; rat monoclonal anti-HA (Roche, cat. 
11867423001) 1:200. Cells were washed extensively before incubation in AlexaFluor 
secondary antibodies (1:200: Molecular Probes) diluted in 3% NGS and mounted onto 
slides with glycerol gelatin containing 2.5% diazobicyclo-[2.2.2] octane (DABCO; 
Sigma Chemical Co.). Images were captured using a Zeiss LSM 510 confocal NLO 
microscope equipped with argon and HeNe lasers and a Zeiss 63X objective lens 
(numerical aperture, 1.4). Images were processed and arranged using Adobe 
Photoshop CS3 and Illustrator CS3. 
Sucrose gradient sedimentation. Capsids were isolated and separated by sucrose 
gradient sedimentation as previously described (Albright, Nellissery et al. 2011). 
Fractions were collected and prepared for Western blot analysis under reducing 
conditions as described above. 
Analysis of conserved residues in UL32. UL32 homologs were identified through a 
sequence similarity search against the KOS UL32 protein on NCBI Blast. Over one 
hundred UL32 homologs were identified using NCBI Blast. The twelve homologs 
shown in Figure 3-3 represent each of the subfamilies of herpesviruses (accession 
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numbers in parentheses): Human herpesvirus [HHV]-1 KOS (AFE62860.1), HHV-2 
(AHG54696.1), HHV-3 (AGL50983.1), HHV-4 (AFY97834.1), HHV-7 (YP_073776.1), 
HHV-8 (AAC57153.1), Bovine herpesvirus [BOHV]-1 (NP_045326.1), BOHV-5 
(YP_003662492.1), Equid herpesvirus 4 [EHV] (NP_045245.1), Suid herpesvirus 1 
[PRV] (AGW01108.1), Gallid herpesvirus [GaHV]-2 (YP_001033961.1), GaHV-3 
(AEI00238.1). 
Generation of substitution mutations. Point mutations were generated in pAPVUL32, 
where UL32 is driven off of the ICP6 promoter (previously described in (Lamberti and 
Weller 1998)), by site-directed mutagenesis using the Quickchange II Site-Directed 
Mutagenesis Kit (Agilent Technologies) per the manufacturer’s protocol. Primers are 
available upon request. Resulting plasmids were sequenced to confirm mutations. 
Protein expression was confirmed by Western blot analysis. 
Transient complementation assay. Vero cells grown to ~75% confluency in 35mm 
dishes were transfected with 1 µg of empty, wild-type, or mutant plasmid using 
lipofectamine 2000 according to the manufacturer’s protocol. At 4 h post-transfection, 
cells were superinfected with hr64FS at an MOI of 3 PFU per cell. At 24 h post-
infection, progeny viruses were harvested and assayed on the 158 cell line for total 
viral yield. The percent complementation was calculated by dividing the titer obtained 
for the mutant plasmid by the titer of the WT plasmid and multiplying by 100. The 
background titers from the empty plasmid samples were subtracted. 
DNA isolation and Southern blot analysis. Vero and 158 cells were infected with 
KOS, hr64, or hr64FS at an MOI of 5 and harvested 16-20 hpi. Total viral and cellular 
DNA was isolated, digested with BamHI and resolved by agarose gel electrophoresis. 
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DNA was transferred to a Gene Screen Plus nylon membrane (New England Nuclear 
Corp.) and hybridized with 32P-labeled probe. The pKBK plasmid, which contains the 
5.9kb BamHI (SQ) junction fragment from KOS (kindly provided by Neal Deluca, 
University of Pittsburgh), was radiolabeled using the Random Primers DNA Labeling 
System (Invitrogen). 
H2O2 treatment. Vero cells were infected with KOS or HA32. At the indicated times 
before harvest, cells were treated with 5mM H2O2 in 2ml serum-free media and 
harvested in 200µl RIPA buffer (reduced) or 10% trichloroacetic acid (TCA) (non-
reduced) at 9 hpi. TCA precipitated samples were resuspended in denaturing n-
ethylmaleimide (NEM) buffer (100mM Tris pH 6.8, 1% SDS, 1mM EDTA, 50mM NEM). 
Samples were subjected to SDS-PAGE in reducing or non-reducing SDS sample buffer. 
Silver staining. After SDS-PAGE, gels were fixed for 1 h in a solution containing 30% 
ethanol and 10% acetic acid and washed twice in 20% ethanol (10 min each wash) and 
once for 20 min with water. The gel was sensitized in 0.1% sodium thiosulfate for 1 min, 
briefly rinsed with water, and incubated in cold 0.1% silver nitrate for 30 min at room 
temperature. Silver nitrate solution was removed; the gel was washed twice with water 
(1 min each wash) and developed with 3% potassium bicarbonate and 0.05% 
formaldehyde. Once the protein bands were detected, staining was terminated by 
replacing the developing solution with 5% acetic acid solution for 10 min. 
Cryo-electron microscopy and image reconstruction. Purified B capsids (3 µl) were 
pipetted onto slightly glow-discharged Quantifoil R2/1 grids (Quantifoil, Jena, Germany), 
blotted and vitrified in an FEI Vitrobot Mk III (FEI, Hillsboro, OR). Grids were 
transferred onto a Gatan 626 cryoholder (Gatan, Pleasanton, CA) and imaged in an 
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FEI Tecnai TF20 microscope operating at 200 kV and 50,000x nominal magnification. 
Images were collected under low-dose conditions on a Gatan UltraScan CCD camera 
with an effective pixel size of 2.14 Ångstroms at the sample. Image reconstructions 
were carried out with the Auto3DEM package (Yan, Sinkovits et al. 2007) using 
randomly oriented models as the starting point in each case (Yan, Dryden et al. 2007). 
Resolutions were estimated where the Fourier shell correlation dropped below 0.5. For 
the control KOS sample of empty capsids, 412 capsid images were collected from 57 
micrographs and 370 were used to calculate the final map to 33 Å resolution. The 
hr64FS sample yielded 1001 capsid images from 104 micrographs, and 900 were 
included in the final map to a resolution of 21.4 Å. 
Thiol modifications. Vero cells were infected with KOS, hr64FS or hr81-1 virus and 
harvested in 10% TCA at 10 hpi. Samples were centrifuged at 13,000 rpm for 30 min in 
a bench-top centrifuge. TCA was aspirated and the pellet was washed with 5% TCA 
followed by another centrifugation. After aspiration, pellets were allowed to dry and 
resuspended in denaturing buffer (6M Urea, 200mM Tris pH 8.8, 10mM EDTA, 0.5% 
SDS) containing 20mM NEM to block free thiols. Equal volumes of 20% TCA were 
added to the samples to precipitate the proteins in a total concentration of 10% TCA. 
After wash, samples were resuspended in denaturing buffer containing 50mM DTT. 
DTT was quenched and newly exposed thiols were modified with the addition of 
100mM 4-acetamido-4’- maleimidylstilbene	  (AMS).	  Reducing loading buffer was added 
to samples and proteins were separated by SDS-PAGE.   
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Results 
UL32 is a late protein with an unusually dynamic intracellular localization pattern  
In this study, we took advantage of an HSV virus expressing HA-tagged UL32 
(HA32) to monitor the kinetics of UL32 expression under natural infection conditions. 
Figure 3-1A shows that in cells infected with the wild-type virus (KOS strain), UL32 was 
maximally expressed at 24 h post infection (hpi), consistent with late expression 
kinetics. In cells infected with HA32, a similar pattern was observed (Fig. 3-1A). In 
order to confirm that this expression pattern reflected true late kinetics, infected cells 
were treated with the viral DNA polymerase inhibitor, phosphonoacetic acid (PAA) to 
prevent viral DNA synthesis. In PAA-treated cells infected with KOS or HA32, UL32 
expression was prevented, demonstrating that UL32 is a true late protein (Fig. 3-1A). 
This is the first demonstration that UL32 protein is expressed with true late kinetics, 
although a previous report suggested that UL32 mRNA was expressed with late 
kinetics (Holland, Sandri-Goldin et al. 1984). In order to demonstrate that the HA-
tagged version of UL32 (HA-UL32) is functional, growth curves of virus produced from 
Vero cells infected with KOS or HA32 were performed. Figure 3-1B shows that these 
viruses exhibited identical growth patterns.  
UL32 was previously reported to localize predominantly to the cytoplasm of 
infected cells although a small fraction was observed within replication compartments 
at 18 hpi (Chang, Poon et al. 1996). A similar pattern was observed in cells transiently 
expressing UL32 and superinfected with a UL32 null virus (Lamberti and Weller 1998). 
The predominantly cytoplasmic localization pattern was somewhat surprising 
considering reports that UL32 is essential for encapsidation, and all of the other viral 
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Figure 3-1. HA32 resembles wild type virus in protein expression and viral growth 
properties. A) Vero cells were infected with KOS or HA32 at an MOI of 3 and collected at 
the indicated times post infection. Samples were harvested in reducing SDS sample buffer 
and resolved by SDS-PAGE. Proteins were detected by immunoblotting with the indicated 
antibodies. B) Growth curves of KOS or HA32 propagated on Vero cells at an MOI of 0.1. 
Mean values of three independent experiments are plotted and deviations are represented 
by error bars.
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 proteins essential for procapsid assembly and encapsidation have been reported to 
localize to replication compartments in the nucleus (Lamberti and Weller 1998, Taus, 
Salmon et al. 1998, Higgs, Preston et al. 2008, Scholtes and Baines 2009). To re-
examine the intracellular location of UL32, cells were infected with HA32 and 
processed for immunofluorescence at various times post infection (Fig. 3-2). ICP8 
staining served as an infection control and to mark replication compartments (Quinlan, 
Chen et al. 1984), and cells were counterstained with the DNA dye, TOPRO3, to detect 
cell nuclei. Interestingly, at 6 hpi UL32 was predominantly detected in replication 
compartments; however, at later times (24 hpi), a mostly cytoplasmic staining pattern 
was observed. To examine this phenomenon more quantitatively, we used ImageJ 
software to analyze the levels of fluorescent intensity in the cytoplasm, nucleus and 
within replication compartments (illustrated by the yellow box in Fig. 3-2B). At 6 hpi the 
localization of UL32 strongly correlated with that of ICP8 within the nucleus suggesting 
that it was present within replication compartments. At 9 hpi UL32 was more diffusely 
localized within the nucleus although most UL32 was observed in replication 
compartments. It should also be noted that some UL32 was observed in the cytoplasm 
at 9 hpi. At 23 hpi UL32 localization no longer correlated with that of ICP8 and was 
detected in a diffuse pattern throughout the cell. These data reveal that the localization 
of UL32 progressed during infection from an initial localization within replication 
compartments to a diffuse localization in both the nucleus and the cytoplasm. Thus, 
although UL32 is initially observed in replication compartments, in contrast with other 
viral proteins that play roles in encapsidation, it is not retained there as the infection 
progresses. We also observed large perinuclear foci containing HA-tagged UL32 at 24 
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Figure 3-2. UL32 changes localization during infection. A) Vero cells were infected with HA32 at an MOI 
of 0.1. At 6, 9 and 24 hrs post infection, cells were fixed in 4% PFA and permeabilized in acetone followed by 
staining for ICP8 (red, mouse antibody) and HA (green, rat antibody). TOPRO-3 staining was performed to 
visualize the nucleus. Scale bar is 5uM. B) Merged images in A were analyzed by ImageJ software. Yellow 
boxes indicate the area used to measure fluorescent intensity. Blue arrows mark the edges of the nucleus as 
indicated by the TOPRO-3 staining. At least 100 cells for each time point were examined, and the staining 
patterns shown in all three panels represent that seen in nearly all cells on the coverslip.
B.
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 hpi (Fig. 3-2) or as early as 5 hpi at a higher MOI of 3 (data not shown). Although 
HA32 and KOS exhibited identical growth curves, we cannot rule out that these foci 
were caused by the HA tag on UL32; they were not observed in previous reports using 
a rabbit polyclonal antibody (Chang, Poon et al. 1996) or an EE-tagged UL32 (Lamberti 
and Weller 1998). We ruled out the possibility that these foci represent aggresomes 
caused by the accumulation of misfolded proteins since they did not contain either 
Hsc70 or Hsp70 (data not shown), hallmarks of previously described aggresomes 
(Muchowski and Wacker 2005). We are intrigued by the possibility that they are related 
to a second function of UL32 in the cytoplasm, and additional experiments will be 
required to investigate this possibility. 
Conserved C-X-X-C motifs are required for infection 
 UL32 is cysteine rich and contains C-X-X-C motifs that are reminiscent of 
cysteine rich motifs present in thiol-disulfide oxidoreductases such as thioredoxin. 
Oxidoreductases are conserved from bacteria to humans and function as antioxidants 
involved in redox balance (Chivers, Laboissiere et al. 1996, Chivers, Prehoda et al. 
1997, Fomenko and Gladyshev 2003, Becerra, Delaye et al. 2007). For example, 
thioredoxin is sensitive to oxidation, and its antioxidant activity is coordinated through 
its C-X-X-C domain (Chivers, Laboissiere et al. 1996, Chivers, Prehoda et al. 1997, 
Fomenko and Gladyshev 2003, Becerra, Delaye et al. 2007). Figure 3-3 shows that 
UL32 and homologs from all three subfamilies of herpesviruses contain five conserved 
cysteine-containing motifs. Sequence alignment using the Clustal W program revealed 
extensive conservation of cysteines especially within motifs I, III, IV, and V (Fig. 3-3). 
Motifs I and IV fit the C-X-X-C pattern while motif V contains a well conserved H-X-X-
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HSV-1    pClVCR LCaKcL dCARllDCt   EClLCn KHmFCDPmCA
HSV-2    pClVCR LCaKcL dCARllDCt   EClLCn KHmFCDPmCA
HHV-3    aClVCR LCmKsL dCARmvDCs   ECmLCc KHLFCDlLCA
HHV-4    tCrVCd LCyycL tCkdsqDvp   iCpLCe KHLFCDPLCA
HHV-7    rCniCs LCyKcn -----des-   vinyCq KHfFCDPLCi
HHV-8    pCrVCq LCffcL rtd-keeat   vClLCe KHLFCDPLCA
BOHV-1   pCaVCR LCaKsL eCARlvDCs   ECvLCn KHLFCDPmCA
BOHV-5   pCvVCR LCaKsL eCARlvDCs   ECvLCn KHLFCDPmCA
EHV      lCliCR LCtKtL eCAkmiDCs   ECvLCn KHLFCDPmCA
PRV      pCrVCR LCaKaL ----vaDar   EClLCn KHLFCDPLCA
GaHV-2   sCaVCk LCfKsq eyARpleCf   ECvLCn KHfFCDPLCA
GaHV-3   qClVCR LCsKcL dCARsveCn   EClLCn KHfFCDPmCc
Cons.    -C-VCR LC-K-L -CAR--DC-   EC-LCN KHLFCDPLCA
      CxxC   CxxC  CxxxxxC    CxxC  HxxCxxxC
Figure 3-3. UL32 homologs are found in all three subfamilies of herpesvi-
ruses. Sequence alignments were performed on UL32 homologs from herpes-
viruses from the ????????????????????????? Residues of interest are highlighted 
??????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????
???????????????????????????????????
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 C-X-X-X-C reminiscent of a motif found in zinc-coordinating proteins responsive to 
disulfide stress (Kang, Paget et al. 1999, Song, Dove et al. 2003). This motif may be 
responsible for the observed zinc-binding properties of UL32 (Chang, Poon et al. 1996). 
 To test whether these conserved motifs are essential for UL32 function, each 
cysteine was mutated to alanine by site directed mutagenesis to preserve the 
hydrophobic nature of cysteines, and the histidine in motif V was mutated to the 
glutamine to preserve the hydrophilic nature at that position. Plasmids bearing these 
mutations were tested for their ability to complement a UL32-null virus (hr64FS) for 
production of infectious virus (Fig. 3-4). Consistent with the lack of conservation in 
motif II, mutations in cysteines 155 and 158 resemble wild type UL32 in their ability to 
complement the null mutant. Most of the other cysteine mutants in motifs I, III, IV and V 
fail to complement hr64FS suggesting that they are essential for UL32 function, 
although mutants altered at cysteine 291 in motif III and cysteine 498 in motif V are 
capable of partial complementation. These data suggest that for two of the three most	  
highly conserved motifs (I and IV), both cysteine residues are essential, and for motifs 
III and V, at least one of the conserved residues is essential. The second cysteine in 
motif II is not conserved and mutations in both cysteines is tolerated. Thus the degree 
of conservation correlates well with the results of the mutational analysis. 
UL32 is sensitive to oxidation 
 The sequence similarities between UL32 and redox sensitive proteins led us to 
ask whether UL32 itself is sensitive to oxidative stress. Redox sensitive proteins, such 
as Keap1 or thioredoxin-like proteins have exposed reactive thiols that serve as 
molecular switches that are modified under oxidizing conditions. These modified forms  
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Figure 3-4.  Mutagenesis of conserved residues in Motifs I,III, IV and V abolish 
complementation ability. Alanine substitution mutations were made at every cysteine in 
Motifs I-V, as well as a histidine-to-glutamine mutation at amino acid 498. A transient 
complementation assay was used to test the ability for the mutant proteins to rescue the 
UL32-null virus hr64FS. Plasmid DNAs containing each mutation were transfected into 
Vero cells followed by superinfection with hr64FS, and the resulting titer was determined 
on 158 cells. Error bars represent the standard deviation of three separate experiments.
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can be detected by changes in mobility observed by non-reducing SDS-PAGE 
(Delaunay, Pflieger et al. 2002, Zhang and Hannink 2003, Brown, Day et al. 2013). 
Vero cells were infected with HA32 at an MOI of 3 for 9 hours, treated with 5mM H2O2 
for various times and harvested in the presence of NEM buffer to prevent spontaneous 
formation of disulfide bonds upon lysis (Fig. 3-5 lanes 4-8). Lanes 1 and 2 show control 
samples of cells infected with KOS or HA32 which were not treated with H2O2 and 
harvested in RIPA buffer. Lysates were subjected to SDS-PAGE under reducing (lanes 
1 and 2) and non-reducing conditions (lanes 4-8) and analyzed by Western blot 
probing with anti-HA antibody. Lysates treated with NEM, but not treated with H2O2, 
contain a prominent 64 kDa band representing NEM-modified monomeric UL32 (Fig 3-
5, lane 4). In cells treated with 5mM H2O2, slower migrating species, most notably an 
~130 kDa band, were observed that became more prominent with time (Figure 3-5, 
lanes 4-8) and may represent hetero- or homo-dimeric forms of UL32. The slower 
migrating species were absent in samples treated with H2O2 for 30 min followed by 
treatment with 100mM DTT (data not shown). These results suggest that exposed 
thiols in UL32 are redox-sensitive and form disulfide-mediated complexes under 
oxidizing conditions.  
Generation and characterization of a new null UL32 mutant  
Our previously isolated UL32 mutant, hr64, expresses the N-terminal 273 
residues of UL32 including the first two of the three C-X-X-C motifs (Lamberti and 
Weller 1998), raising the possibility that this fragment of UL32 might mask the 
phenotype of a virus completely lacking UL32. Thus a new UL32 mutant virus (hr64FS) 
containing  a  frame-shift   mutation  was  generated,  resulting  in  the  creation  of  two 
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Figure 3-5. UL32 forms slower migrating species in the presence of H2O2. 
Vero cells were infected with HA32 at an MOI of 3.  At 9 hpi cells were washed with 
PBS and overlaid with 2 ml of SFM either with or without 5mM H2O2. Cells were 
washed with PBS and collected in RIPA buffer without NEM (lanes 1 and 2) or TCA 
precipitated followed by resuspension in NEM buffer (lanes 4-8) at the indicated 
times. Proteins were separated by reducing or non-reducing SDS-PAGE and 
analyzed by Western blot using mouse anti-HA antibody. The molecular marker 
(lane 3) represents from top to bottom 250, 150, 100 and 50 KDa. 
1 2 3 4 5 6 7 8 Lane
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tandem premature stop codons at amino acids 56 and 57. This position was chosen to 
avoid altering the adjacent divergently transcribed UL31 gene. Figure 3-6A shows that 
hr64FS was unable to grow on Vero cells but replicates efficiently on the UL32-
complementing cell line, named 158. Figure 3-6B shows that wild type levels of viral 
DNA were observed in cells infected with hr64 or hr64FS; however, S and Q fragments 
representing cleavage products were not observed in hr64- or hr64FS-infected Vero 
cells consistent with an encapsidation defect. The encapsidation defect was rescued 
when the virus was propagated on 158 cells. Thus hr64FS exhibits the same growth 
phenotype and encapsidation defect as hr64.  
Encapsidation of viral genomes requires the assembly of a competent procapsid 
containing major capsid protein VP5, triplex proteins VP19C and VP23, internal 
scaffold and protease and a portal ring. In order to determine whether the defect in 
packaging was due to aberrant capsid composition or morphology, we examined the 
ability of hr64FS to assemble structures that resemble procapsids. Procapsids cannot 
be isolated directly from infected cells because they are fragile and spontaneously 
mature into angular B-capsids that have a similar protein composition to procapsids 
except that the scaffold proteins have been proteolytically processed (Newcomb, Trus 
et al. 2000). B-capsids from cells infected with KOS, hr64FS or hr81-1 were purified by 
sucrose gradient sedimentation and analyzed by SDS-PAGE and silver staining to 
examine their protein composition. Hr81-1 is a UL15 null virus, and since UL15 is a 
component of the HSV terminase, this mutant also exhibits a packaging defect. Hr81-1 
is capable of assembling B-capsids and thus serves as a control to ensure that 
differences between KOS and hr64FS are due to the absence of UL32 and  not  to  the  
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Figure 3-6. UL32 mutants, defective in growth, synthesize wild-type levels of viral DNA but are unable to 
cleave and package it. A) Growth curves of KOS, hr64FS or hr64 propagated on Vero or 158 cells. Mean 
values of three independent experiments are plotted and standard deviations are represented by error bars. B) 
Vero or 158 cells were infected with KOS, hr64 or hr64FS and viral DNA was analyzed by Southern blot as 
described in Materials and Methods. The blotted DNA was hybridized with 32P-labeled probe containing the 
BamHI SQ fragment. SQ represents viral DNA junctions and S and Q represent viral DNA termini. 
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encapsidation defect. Figure 3-7A demonstrates that B-capsids isolated from hr64FS-
infected cells have a protein composition indistinguishable from capsids isolated from 
KOS- or hr81-1-infected cells. Purified capsids were also analyzed by cryo-EM as 
described in Materials and Methods, and the cryo-EM reconstructions shown in Fig. 3-
7B reveal no differences between the hr64FS and KOS capsids. We conclude that 
capsids assembled in the absence of UL32 resemble those assembled by wild-type 
virus suggesting that there are no obvious defects in capsid composition or assembly. 
We previously reported that hr64-infected cells exhibited inefficient localization 
of the major capsid protein (VP5) to replication compartments (Lamberti and Weller 
1998), leading to the hypothesis that UL32 may function as a virally encoded 
chaperone needed for efficient localization of one or more of the capsid proteins. We 
analyzed the localization patterns of VP5 and the rest of the viral capsid proteins in 
cells infected with the new UL32 mutant hr64FS (Fig. 3-8). Surprisingly, despite our 
earlier report that VP5 was mislocalized in cells infected with hr64, in cells infected with 
hr64FS, VP5 localized to replication compartments similar to the pattern seen in KOS-
infected cells. This experiment has been repeated with three different VP5 antisera, 
and in each case VP5 was shown to localize to replication compartments in cells 
infected with either hr64 or hr64FS (data not shown). The reason for this apparent 
discrepancy is unclear but may be related to differences in culture conditions such as 
passage number of the cells or levels of glutamine or oxygen in the media. One or 
more of these differences could alter the folding environment in cells leading to protein 
mislocalization. We also monitored the behavior of other capsid proteins including 
VP22a and VP23,  and  both  were  found  to  localize  to  replication  compartments  in  
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Figure 3-7.  hr64FS capsids are indistinguishable from KOS capsids. A) Viral 
capsids were isolated by sucrose gradient sedimentation from Vero cells infected with 
KOS, hr64FS or hr81. Dilutions of B-capsids were separated by reducing SDS-PGE and 
silver stained. B) Cryo-EM analysis and reconstruction of B-capsids isolated from KOS or 
hr64FS-infected cells - surface representations of the capsid exterior (left) and interior 
(middle) and a grey-scale central section (right). Capsid subunits are indicated as 
h-hexons, p-pentons, t-triplexes and cvsc-capsid vertex specific component. Icosahedral 
2 and 5-fold symmetry axes are also marked. Bar = 200Å.
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Figure 3-8. Capsid proteins localize to replication compartments in the absence of UL32. Vero cells were infected 
with KOS or hr64FS at an MOI of 3. Infected cells were fixed with 4% PFA and permeabilized in acetone.  Cells were 
stained with antibodies to ICP8 (red channel) plus the capsid proteins indicated (green channel) as described in materi-
als and methods. 
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hr64FS-infected cells in a similar fashion to their localization in KOS-infected cells (Fig. 
3-8). We conclude that UL32 does not influence the localization of capsid proteins, 
consistent with the observation that protein composition and capsid architecture 
appears to be normal in the absence of UL32 (Fig. 3-7A and B).  
UL32 influences disulfide bond status of viral proteins, including the viral 
protease (VP24)  
 We have previously reported that mature HSV capsids are extensively cross-
linked by disulfide bonds (Szczepaniak, Nellissery et al. 2011) and that the UL6 portal 
ring contains inter-subunit disulfide bonds (Albright, Nellissery et al. 2011). This raises 
the question of how disulfide bond formation in the portal is regulated, especially in a 
cellular environment that is generally thought to be reducing (Albright, Nellissery et al. 
2011). We hypothesize that UL32 acts as a regulator of disulfide bond formation. To 
test this hypothesis, we took advantage of the thiol-modifying reagent AMS, a 
maleimide derivative that reacts with free cysteines, adding ~500 Daltons to each 
cysteine that has a free sulfhydryl. If UL32 were responsible for disulfide bond 
regulation we would expect a difference in the number of free cysteines available for 
modification with AMS in cells infected in the presence and absence of UL32. Vero 
cells were infected with KOS, hr64FS or the packaging mutant hr81-1. At 11 hpi 
infected cells were TCA-precipitated, resuspended in denaturing buffer containing NEM 
to block free thiols, reduced with DTT to free thiols participating in disulfide bonds and 
subsequently treated with AMS to modify the newly freed thiols as described in 
Materials and Methods. Figure 3-9 shows that in the absence of UL32, both the viral 
protease, VP24 and UL6 migrate slower than they do in cells infected with KOS or  
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Figure 3-9.  UL32 modulates disulfide bond formation in the viral proteins.  Vero cells were infected with 
KOS, hr64FS or hr81 at an MOI of 3 and harvested in 10% TCA at 10 hpi. Free thiols were blocked with NEM, 
followed by reduction with DTT then treatment with the thiol alkylating agent AMS. Proteins were resolved by 
reducing SDS-PAGE and detected by immunoblotting with anti-VP24 or anti-UL6 antibody. 
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hr81-1-infected cells. Hr81-1 was included in this experiment to show that the disulfide 
bond alterations seen in hr64FS-infected cells were not the result of an encapsidation 
defect. These shifts were not observed in the absence of AMS and suggest that in 
hr64FS-infected cells, protease and UL6 contained disulfide bonds not observed in 
cells infected with KOS or hr81. Interestingly, similar shifts were observed in the minor 
capsid proteins UL25 and VP19C (data not shown). These results are consistent with 
the hypothesis that UL32 regulates disulfide bond formation and that the presence of 
UL32 may function to prevent premature disulfide bond formation in a number of viral 
capsid proteins.  
 
Discussion 
In this study two new viruses were used to examine the role of UL32 in the 
encapsidation of HSV-1 DNA: HA32, containing an HA-tagged UL32 protein (HA32) 
and a null mutant (hr64FS) containing a frameshift mutation. HA32 resembles wild type 
virus in growth and encapsidation while hr64FS is defective for both. Several 
observations were made. (i) Hr64FS assembled B-capsids that resemble wild type B-
capsids in protein composition and appearance by cryo-EM (Fig. 3-7B); however, they 
were unable to encapsidate viral genomes. (ii) Although it was previously reported that 
UL32 is mostly cytoplasmic with some minor staining in the nucleus, a time course 
experiment (Fig 3-2) revealed a dynamic localization pattern. UL32 was found 
predominantly in replication compartments early in infection, while later its localization 
became cytoplasmic/nuclear diffuse. (iii) We confirmed that UL32 is a true late protein. 
(iv) Two highly conserved C-X-X-C motifs within UL32 were shown to be essential for 
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viral growth. (v) UL32 was shown to be redox-sensitive. (vi) UL32 influenced the 
formation of disulfide bonds in the viral proteins UL25, VP19C, UL6 and the viral 
protease, VP24.  
 The ability to assemble B-capsids that are indistinguishable from those seen in 
cells infected with wild type HSV suggests that UL32 is not required for the assembly of 
procapsids per se. On the other hand, we have confirmed that procapsids assembled 
in cells infected with a UL32 mutant fail to initiate encapsidation. Protease activation 
marks the initiation of the encapsidation process; however, the mechanism by which 
protease is regulated is not understood. The formation of inter- and intramolecular 
disulfide bonds is generally recognized to regulate a wide range of cellular processes. 
We have previously shown that disulfide bonds are essential for capsid stability and for 
the formation and or stability of the UL6 portal ring (Albright, Nellissery et al. 2011, 
Szczepaniak, Nellissery et al. 2011). It is possible that the HSV protease is regulated 
by redox state. This suggestion may be consistent with previous reports suggesting 
that the HCMV protease is regulated by disulfide bond formation. Alternatively, 
initiation of encapsidation may be triggered by redox-stimulated changes in the portal 
ring. Thus encapsidation may be regulated through a thiol-disulfide exchange 
mechanism involving protease or portal or both.  
The suggestion that UL32 may perform a thiol-disulfide exchange reaction is 
consistent with the observations that UL32 itself is redox sensitive and that it contains 
C-X-X-C motifs reminiscent of those found in a number of other thiol-disulfide 
oxidoreductases. We now report that these conserved C-X-X-C motifs are essential for 
viral growth. UL32 may act directly on protease or UL6 by catalyzing the formation or 
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breaking of disulfide bonds; alternatively, UL32 may exert indirect effects by altering 
the cellular milieu to provide an environment conducive for disulfide bond formation.  
The localization of UL32 in infected cells may also provide some clues as to its 
function. Previous reports that UL32 is predominantly a cytoplasmic protein were hard 
to reconcile with the phenotype of UL32 mutants that suggested a role in encapsidation. 
The observation that UL32 was found to localize predominantly to replication 
compartments early in infection and in the cytoplasm and nucleus at later stages is 
consistent with additional functions for UL32 at a stage post-encapsidation. Our finding 
that in the absence of UL32, capsid proteins UL6, UL25 and VP19C exhibited disulfide 
bonds not seen in wild-type infection is of interest. We and others have found that the 
cellular environment becomes oxidized during HSV-1 infection (Palamara, Perno et al. 
1995, Nucci, Palamara et al. 2000, Vogel, Cinatl et al. 2005, Mathew, Bryant et al. 
2010, Gonzalez-Dosal, Horan et al. 2011) (Albright manuscript in preparation), and an 
oxidized environment may promote disulfide bond formation. Although some disulfide 
bonds may be beneficial for the virus, it is also possible that an oxidizing environment 
could lead to aberrant disulfide bond formation between exposed reactive thiols that 
would be deleterious to the virus. We suggest that UL32 may serve to protect sensitive 
thiols from aberrant or deleterious disulfide bond formation. Thus, in addition to a 
possible role in the nucleus regulating protease and/or UL6, UL32 may play additional 
roles required for capsid maturation in the cytoplasm, possibly by protecting reactive 
thiols. Alternatively, UL32 may catalyze the formation of disulfide bonds to regulate 
specific processes, such as protease activation.  
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This study provides the first evidence that HSV may encode a virally-encoded 
oxidoreductase. Other large DNA viruses, which require disulfide bonds, have been 
shown to encode enzymes that function as oxidoreductases (Iyer, Aravind et al. 2001). 
For instance, vaccinia virus encodes three oxidoreductases (E10R, A2.5L and G4L) 
which participate in a thiol-disulfide relay responsible for modulating disulfide bonds in 
the cytoplasm (Senkevich, White et al. 2002). It is becoming increasingly clear that 
oxidative stress and cellular responses to it play critical roles in modulating a large 
number of biological processes including pathogenesis by bacterial and viral infections. 
Many viruses including HSV have been shown to induce oxidative stress, and 
antioxidants have shown promise in the treatment of viral infection (Palamara, Perno et 
al. 1995, Garland and Fawzi 1999, Beck, Handy et al. 2000, Nucci, Palamara et al. 
2000, Cai, Chen et al. 2003, Abdalla, Ahmad et al. 2005, Vogel, Cinatl et al. 2005, Tian, 
Jiang et al. 2010). Viral proteins that play roles in sensing and responding to changes 
in redox status may thus provide targets for therapeutic intervention. The suggestion 
that UL32 encodes a redox sensitive chaperone responsible for modulating disulfide 
bond formation in HSV-infected cells indicates that UL32 itself may represent a novel 
and promising drug target for controlling HSV infections.   
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Chapter 4 
 
A pro-oxidant environment may be required for efficient early and 
late gene expression of herpes simplex virus type 1. 
 
Brandon S. Albright, Renata Szczepaniak, and Sandra K. Weller 
 
Abstract 
Previous reports have shown the HSV-1 induces the generation of reactive oxygen 
species (ROS) and requires a pro-oxidant environment for efficient viral growth; 
however, the role of ROS during HSV-1 infection is not clear. In this study, we 
confirmed that the intracellular environment becomes oxidized during viral infection 
using a genetically-encoded redox-sensitive GFP (roGFP2). In addition, we treated 
HSV infected cells with the antioxidant glutathione (GSH) and investigated viral 
growth at 6, 12, 24 and 48 hours. GSH treatment reduced HSV growth in Vero and 
HeLa cells, and to a greater extent, normal human fibroblast (NHFs) and human 
embryonic lung (HEL) fibroblasts. Growth yields were affected at multiplicities of 
infection (MOIs) of both 0.1 and 5, with a substantial defect in viral growth as early 
as 6 hours post infection (hpi) at an MOI of 5. Western blot analysis revealed that 
GSH treatment reduced early (E) and late (L) gene expression but not expression of 
the immediate early (IE) gene, ICP4. We explored whether the ROS-generating 
NADPH-oxidase (NOX) family of enzymes was required for HSV infection. We used 
a pan-NOX inhibitor, diphenylene iodonium (DPI) and found that inhibiting NOX 
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activity reduced viral growth at early stages. Similar to what we observed with GSH 
treatment, DPI treatment delayed viral replication compartment formation and E and 
L gene expression. These data suggest that NOXs may contribute to a pro-oxidant 
state during infection, which is necessary for an early step in the viral lifecycle.  
 
Introduction 
 
Many viruses, including herpes simplex virus 1 (HSV-1), have been shown to 
increase the levels of intracellular reactive oxygen species (ROS) during infection 
(reviewed in (Fraternale, Paoletti et al. 2009, Campagna and Rivas 2010, Bottero, 
Chakraborty et al. 2013, Paiva and Bozza 2014). ROS are potentially toxic 
metabolites generated through the incomplete reduction of molecular O2. Despite 
the ability of ROS to cause damage to many macromolecules, it is becoming 
increasingly apparent that they are important secondary messengers involved in a 
number of biological processes (Sauer, Wartenberg et al. 2001, Valencia and Moran 
2004, Collins, Chouchani et al. 2012). The balance of intracellular ROS is crucial to 
cell physiology and is coordinated by a number of systems that generate ROS 
(discussed below) or work to clear ROS. The predominant buffer against intracellular 
ROS is the small tripeptide, glutathione (GSH), which exists in millimolar 
concentrations within the cell. When ROS are present, GSH serves as a scavenger. 
Furthermore, a number of enzymes, such as thioredoxin, peroxiredoxin, superoxide 
dismutase (SOD), etc., work to keep the intracellular redox environment stable. 
Perturbations in the redox balance can result in either reductive or oxidative stress 
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(OS), which elicits a response to bring the cell back to homeostasis. When this 
balance tips in favor of the oxidants, it can cause severe cellular and tissue damage 
if unresolved.   
The two major intracellular sources of ROS are the mitochondria and the 
NADPH-oxidase (NOX) family of enzymes. Mitochondria generate ROS as an 
accidental by-product of oxidative phosphorylation, which occurs when electrons 
escape from the electron transport chain and react with molecular oxygen. NOXs, on 
the other hand, are a unique class of trans-membrane enzymes designed to 
intentionally generate ROS (Bedard and Krause 2007). The NOX family comprises 
seven members (NOXs 1-5 and Duox 1,2) which have specific tissue and cell-type 
distributions (Bedard and Krause 2007). Although the role of NOX2 has been well 
established in the production of ROS for pathogen clearance (Sumimoto, Miyano et 
al. 2005), the roles of the other NOXs are poorly defined (Bedard and Krause 2007).  
It has been well documented that many viruses not only tolerate, but also 
thrive, in a pro-oxidant environment (reviewed in (Peterhans 1997, Fraternale, 
Paoletti et al. 2009, Paiva and Bozza 2014)). HIV, for instance, induces ROS to 
trigger activation of the cellular transcription factor NF-kB, and in turn upregulates 
viral gene expression (Nabel and Baltimore 1987, Staal, Roederer et al. 1990). In a 
recent study, NOX4-derived ROS was shown to be important for influenza infection 
in a cell culture model (Amatore, Sgarbanti et al. 2015). During influenza infection, 
the production and release of progeny virus requires the nuclear export of viral 
ribonucleoproteins (vRNPs). This export has been shown to require caspase 
activation and the subsequent enlargement of nuclear pores (Muhlbauer, 
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Dzieciolowski et al. 2015). When NOX4 activity was inhibited, vRNPs accumulate in 
the nucleus, suggesting that NOX4 mediated ROS plays a role in caspase activation 
during influenza infection. Thus, intentional ROS generation through NOX activation 
may be a common strategy used by viruses to hijack specific cellular pathways for 
their own benefit. 
Several lines of evidence suggest that HSV-1 induces and requires a pro-
oxidant environment: 1) infection has been reported to cause an immediate and 
sustained drop in intracellular GSH pools (Palamara, Perno et al. 1995, Nucci, 
Palamara et al. 2000, Vogel, Cinatl et al. 2005), 2) restoration of GSH levels by 
antioxidant treatment has been reported to inhibit viral growth (Palamara, Perno et 
al. 1995, Nucci, Palamara et al. 2000, Vogel, Cinatl et al. 2005), 3) intracellular ROS 
can be detected as early as 1 hpi using the redox-sensitive fluorescent dyes 
dichlorodihydrofluorescein – diacetate (DCHF-DA) (Schachtele, Hu et al. 2010, 
Gonzalez-Dosal, Horan et al. 2011, Hu, Sheng et al. 2011)  or hydroxyphenyl 
fluorescein (HPF) (Kavouras, Prandovszky et al. 2007) and 4) oxidized proteins 
accumulate in HSV-infected cells (Mathew, Bryant et al. 2010). Collectively, these 
findings are consistent with the idea that HSV induces and requires an oxidizing 
environment; however, how and why the virus has evolved to tolerate and thrive in 
an oxidizing environment is unclear.  
In this study we set out to define the stage of the viral lifecycle that is impaired 
by GSH treatment and to gain a better understanding of how oxidative stress is 
induced by HSV. Here, we confirmed that HSV-1 infection shifts the cellular 
environment to a pro-oxidant state. We also showed that GSH treatment inhibited 
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viral growth in Vero cells, HeLa cells, normal human fibroblasts (NHFs), and human 
embryonic lung (HEL) cells. GSH treatment reduced viral growth by over 90% as 
early as 6 hpi when the infection was carried out at an MOI of 5. Western blot 
analysis revealed that the IE gene ICP4 was expressed efficiently in treated cells; 
however, early E and late L gene expression was delayed. Consistent with these 
findings, we observed that antioxidant treatment resulted in delayed replication 
compartment formation. We tested the hypothesis that NOX-derived ROS was 
important for HSV growth and found that inhibiting NOX activity, using the chemical 
inhibitor DPI, led to similar defects in viral growth, protein expression and replication 
compartment formation as found during antioxidant treatment. In summary, we 
suggest that NOX activity is necessary for generating a pro-oxidant environment and 
that this type of an environment is required for efficient infection. We also propose 
that the oxidizing environment may be required for efficient expression of E and L 
viral genes. 
  
 
Materials and methods 
 
Cell lines and viruses. African green monkey kidney cells (Vero CC181; American 
Type Culture Collection, Rockville, MD), HeLa cells and human foreskin fibroblasts 
(HFFs), were maintained and propagated in Dulbecco’s modified Eagle’s medium 
(DMEM, Invitrogen, Carlsbad, CA) supplemented with 5% or 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin (P/S). Normal human fibroblasts were 
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immortalized with hTert, a gift from the lab of Douglas McCarty, and were cultured in 
MEM supplemented with 15% FBS, 2 mM L-glutamine and 1% P/S. Human 
embryonic lung cells were cultured in MEM containing 10% FBS and 1% P/S. The 
KOS strain of HSV-1 was used as the wild-type virus. Cell maintenance and 
infections were carried out at 37oC.  
Detection of ROS with roGFP2. The plasmid carrying roGFP2 was purchased from 
the University of Oregon. Vero cells were transfected with roGFP2 using 
Lipofectamine200 according to the protocol. 16 hours post-transfection, cells were 
treated or infected and harvested at the appropriate times in ice-cold 1% NP-40 
buffer (20 mM Tris-HCl pH 8.0, 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM 
EDTA, 10 mM NEM). Plates were rocked for 15 min before adding supernatants to 
wells of a 96-well plate and immediately analyzed. Fluorescence was detected on a 
Beckman Coulter plate reader (PN 987958) at excitation wavelengths of 405 nm and 
488 nm and emission set to 510 nm. Data were processed in excel. 
Cell treatments. Reduced L-glutathione (Sigma, #G4251) was dissolved in serum 
free DMEM or MEM at a stock concentration of 200 mM. Aliquots were stored at -
80oC and diluted in media containing 2.5% to 20 mM just before use. Diphenelyne 
iodonium (Sigma, #D2926) was dissolved in DMSO to a stock concentration of 10 
mM and was diluted to the appropriate concentration in the cell-type specific media 
prior to use. DMSO was added to untreated controls in these experiments, but never 
reached >0.2%. 
Growth curves. Confluent cells were infected with KOS at an MOI of 0.1 or 5. Cells 
and supernatant were harvested at 0, 6, 12, 24 and 48 hours post-infection. After 
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three freeze-thaw cycles, serial dilutions were plated on Vero cells, overlaid with 
DMEM supplemented with 2% FBS and 1% human serum, incubated for 72 h, fixed 
in 4% formaldehyde, and stained with 1% crystal violet solution. Viral plaques were 
counted by eye. 
Western blot analysis. Cells were harvested and proteins were separated by 
reducing SDS-PAGE as previously described and transferred to a PVDF membrane 
(Albright, Nellissery et al. 2011). Membranes were blocked with 5% milk and 
incubated overnight with the following antibodies: 1:1,000, rabbit polyclonal anti-
UL32 1:1,000 (generated by Open Biosystems to synthetic antigenic peptide); 
mouse monoclonal anti-ICP8 1:2,000 (abcam ab20194); mouse monoclonal anti-
VP5 (EastCoast Bio HA018) 1:1,000; mouse anti-Actin (Sigma A5441) 1:10,000.  
Immunofluorescent confocal microscopy. Monolayers of Vero cells were grown 
on glass coverslips prior to infection. Infected cells were washed with 2X phosphate-
buffered saline (PBS), fixed in 4% paraformaldehyde and permeabilized in ice cold 
acetone for 2 min followed by blocking in 3% normal goat serum (NGS) diluted in 
PBS. Cells were incubated in primary antibodies diluted in 3% NGS for 1-2 h at room 
temperature by inverting coverslips onto a drop of antibody dilution. Dilutions of 
primary antibodies in 3% NGS were as follows: monoclonal anti-ICP8 1:200; rabbit 
polyclonal anti-NOX4 (SantaCruz, cat. sc-30141) 1:200. Cells were washed 
extensively before incubation in AlexaFluor secondary antibodies (1:200: Molecular 
Probes), diluted in 3% NGS and mounted onto slides with glycerol gelatin containing 
2.5% diazobicyclo-[2.2.2] octane (DABCO; Sigma Chemical Co.). Images were 
captured using a Zeiss LSM 510 confocal NLO microscope equipped with argon and 
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HeNe lasers and a Zeiss 63X objective lens (numerical aperture, 1.4). Images were 
processed and arranged using Adobe Photoshop CS3 and Illustrator CS3. 
 
 
Results  
 
HSV-1 induced ROS can be detected with a redox-sensitive GFP  
  
 The goal of our study was to investigate the induction and consequences of 
ROS by HSV. To this end, we first wanted to confirm that Vero cells were oxidized 
during HSV infection. Several studies have previously shown that HSV induces 
intracellular ROS. These ROS were measured directly using redox-sensitive 
fluorescent dyes such as dichlorodihydrofluorescein – diacetate (DCHF-DA) 
(Schachtele, Hu et al. 2010, Gonzalez-Dosal, Horan et al. 2011, Hu, Sheng et al. 
2011) or hydroxyphenyl fluorescein (HPF) (Kavouras, Prandovszky et al. 2007). 
These dyes are used ubiquitously as they are cell permeable, allowing for labeling of 
live cells. Another advantage of using these dyes is that they allow for direct 
quantification of ROS. Despite these benefits, there are also limitations to the use of 
these probes. For instance DPH only reacts with highly reactive oxygen species, 
such as the hydroxyl radical (OH.) or peroxynitrate and thus would not be a reliable 
detector of other ROS, such as superoxide (O2-) or hydrogen peroxide (H2O2) 
(Setsukinai, Urano et al. 2003). Conversely, the mechanism of DCHF-DA oxidation 
is poorly understood and can react even in the absence of ROS through reactions 
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with intracellular metals, peroxidases and cytochrome c (Marchesi, Rota et al. 1999, 
Wardman 2007). Furthermore, the oxidation of DCHF-DA can generate O2-, leading 
to an accumulation of the species it is designed to measure (Wrona, Patel et al. 
2005).  
For these reasons, we decided to use a genetically encoded redox-sensitive 
GFP, roGFP2, which is a GFP molecule where two residues on an exposed surface 
of the protein were mutated to cysteines to serve as a sensitive and rapid redox 
switch (Dooley, Dore et al. 2004). Upon oxidation, the cysteines form a disulfide 
bond and induce a conformational change, which causes the protein to preferentially 
excite at 405 nm, as opposed to the 488 nm when reduced. To test whether HSV 
induces oxidation, Vero cells were transfected with an expression plasmid carrying 
roGFP2 as described in materials and methods. 16 hours post transfection, cells 
were infected with KOS and harvested in 1% NP-40 buffer containing 10 mM n-ethyl 
maleimide (NEM) to preserve the redox state of the roGFP2.  NEM alkylates free 
thiols and prevents oxidation of the protein during processing. Cells were also 
treated with 10 mM dithiothreitol or H2O2 to serve as the reduced and oxidized 
controls, respectively. We measured the fluorescence on a plate reader and 
calculated the ratio of 405 nm/ 488 nm (Figure 4-1). We observed that the 
fluorescence ratio slightly increased at 1 hpi and this increase was maintained for at 
least the first 5 hours. Thus, this is the first report using a genetic redox probe to 
confirm that HSV induces an oxidizing environment.  
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Figure 4-1 HSV-1 infection induces oxidation of roGFP2. Vero cells were transfected with a plasmid 
expressing roGFP2. 16 hours post transfection, cells were either treated with the indicated compounds 
or infected with KOS and harvested at the indicted times in a 1% NP-40 buffer. DTT treatment served 
as the reduced control and H2O2 treatment served as the oxidized control. Emission at 510nm was 
measured after excitation with 405nm or 488nm on a plate reader.
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The effect of GSH treatment on HSV growth varies between cell-types and 
culture conditions. 
  
We next wanted to confirm previous reports that GSH treatment was 
inhibitory to viral growth. Unlike other reports that measured viral growth only at 24 
and 48 hours (Palamara, Perno et al. 1995, Vogel, Cinatl et al. 2005), we measured 
viral growth at 0, 6, 12, 24 and 48 hpi to get a more extensive view of when 
antioxidant treatment inhibited viral growth. Vero cells and HFFs were infected at a 
multiplicity of infection (moi) of 2 and incubated in media with or without 20 mM GSH 
(Figure 4-2). Surprisingly, we observed that viral titers at every time point were 
nearly identical between the treated and untreated in both cell types. We also 
repeated these experiments using another antioxidant, N-acetylcysteine, and got 
similar results (data not shown).  
These data are in disagreement with the initial work by Palamara, et al, and 
Vogel, et al, who found GSH to be inhibitory to viral growth in Vero cells and HFFs, 
respectively (Palamara, Perno et al. 1995, Vogel, Cinatl et al. 2005). Upon 
examination of the protocols used in these studies, we noticed that we were using 
Dulbecco’s essential modified media (DMEM); whereas, the groups noted above 
used RPMI 1640 and modified essential media (MEM), which are similar to each 
other. Since DMEM contains ferric nitrate and is supplemented with double the 
nutrients as the other two media types, we next asked whether culture media could 
be  a  reason  for  the  discrepancy  between  our  results  and  previously  published  
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Figure 4-2 KOS infection is not sensitive to antioxidant treatment on Vero cells or HFFs. 
Vero cells or HFFs were infected at an MOI of 2 and incubated in DMEM containing 2.5% serum 
without (UT, gray line) or with (GSH, black line) 10 mM NAC. Samples were collected at the 
specified timepoints and growth was measured by titration on Vero cells. Error bars represent the 
standard deviation of 3 separate experiments 
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reports. For this experiment, we cultured Vero cells in MEM for several passages. 
We then tested the effects of antioxidant treatment during infection of Vero cells 
under these conditions. Strikingly, we saw attenuated growth beginning at 12 hpi in 
the presence of antioxidants (Figure 4-3). These data confirm previous reports that 
the virus is sensitive to antioxidants; however, they illustrate that great care needs to 
be taken when designing experiments to examine redox systems. How the culture 
conditions influenced GSH treatment is unclear, but It is possible that culturing Vero 
cells in DMEM predisposes these cells to stress due to the overabundance of amino 
acids and vitamins. Alternatively, DMEM is supplemented with ferric nitrate, which is 
an iron salt, and it is well known that iron in solution can undergo redox cycling. Both 
MEM and RPMI-1640 contain no iron supplement. 
We next asked whether GSH treatment could inhibit viral growth in other cell 
types. We tested HeLa cells (transformed human cervical epithelial cells), 
immortalized normal human fibroblasts (stably expressing the hTert gene) and a 
primary, non-immortal cell type, Human embryonic lung fibroblasts. Cells were 
infected with KOS at an MOI of 0.1 and incubated in media supplemented with 2.5% 
FBS with or without 20 mM GSH. Infection was reduced by over ten-fold in HeLa 
cells at 48 hpi, although the earlier time points displayed a more moderate reduction 
(Figure 4-4). Strikingly, GSH had a substantially greater impact on viral growth in 
KOS-infected NHFs and HEL cells (Figure 4-4). Antioxidant treatment resulted in a ~ 
2 log decrease in viral yield at 12 hpi and this decrease is sustained for up to 48 hpi. 
Because infection in NHFs and HEL cells had the greatest response to GSH 
treatment, these two cell-types were selected for the rest of our studies. Some types  
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Figure 4-3 Virus grown on Vero cells culture in MEM is susceptible to antioxidant treatment. 
Vero cells were cultured in MEM containing 5% FBS  for several passages before being infected 
with KOS at an MOI of 0.1. Infected cells were incubated in MEM containing 2.5% serum without 
(UT, gray line) or with (GSH, black line) 20 mM GSH. Samples were collected at the specified 
timepoints and growth was measured by titration on Vero cells. Error bars represent the standard 
deviation of 4 separate experiments 
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Figure 4-4 Glutathione treatment reduces viral growth on multiple human cell types. HeLa cells, 
HEL cells or NHFs were infected at an MOI of 0.1 and incubated in MEM containing 2.5% serum without 
(UT, gray line) or with (GSH, black line) 20mM GSH. Samples were collected at the specified timepoints. 
Growth was measured by titration on Vero cells. Error bars represent the standard deviation of 3 separate 
experiments.
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of defects can be overcome by increasing the MOI; therefore, we asked whether 
GSH treatment could block infection at a high MOI. NHFs were infected with KOS at 
an MOI of 5 and treated as described above. Figure 4-5 shows that GSH treatment 
reduced viral growth by 10-fold at 6 hours and nearly 100-fold at 12 hours post 
infection, suggesting that there was a substantial block in the progression of 
infection at an early time. We also observed a similar defect in growth in GSH-
treated HEL cells infected at an MOI of 5 (data not shown). In all, we confirmed that 
GSH treatment blocked HSV infection in several different cell types and during 
infection at low (0.1) and high (5) MOIs.  
 
GSH treatment impairs viral replication compartment formation 
  
During HSV-1 infection, the virus hijacks the host-cell nucleus and forms large 
globular domains called replication compartments. Replication compartments are the 
sites of viral gene transcription, DNA replication and virus assembly. The formation 
and growth of replication compartments depends on the expression of IE and E 
gene products. Thus, replication compartments (RC) serve as a marker for the 
progression of infection, and we used RC formation as a preliminary step to 
determine the stage of infection that was impaired during GSH treatment. NHFs 
were infected with KOS at an MOI of 5, incubate in media with or without 20 mM 
GSH, harvested at 2, 4, 6 and 12 hpi and processed for immunofluorescence 
analysis. Cells were stained with antibodies against the viral single-strand DNA 
binding protein, ICP8, a marker for replication compartments. In the untreated cells  
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Figure 4-5 GSH inhibits viral growth even at high MOI. NHFs were infected at an 
MOI of 5 and incubated in MEM containing 2.5% serum without (UT, gray line) or with 
(GSH, black line) 20mM GSH. Samples were collected at the specified timepoints 
and growth was measured by titration on Vero cells. Error bars represent the stan-
dard deviation of 3 separate experiments. 
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at 2 hpi, there was a mixture of ICP8 staining patterns; some cells had small foci 
while others had large globular structures indicative of progressing replication 
compartments. In the GSH-treated cells, on the other hand, only very small foci were 
observed at 2 hpi (Figure 4-6). Furthermore, the progression of replication 
compartment formation was delayed at all time points when compared to the 
untreated samples. Thus, our data suggest that GSH treatment impairs replication 
compartment formation. 
 
 
Viral gene expression is altered in the presence of GSH. 
  
 The delay in replication compartment formation led us to speculate that viral 
gene transcription may be impaired. During infection, there is a tightly regulated 
cascade of gene expression.   IE gene products are required for the expression of E 
replication proteins which in turn upregulate L gene expression.  DNA synthesis is 
required for true-late gene expression. We set out to assess the expression of viral 
genes from each of these kinetic classes by Western blot analysis. Cells were 
infected in the absence or presence of GSH for varying lengths of time, and viral 
protein expression was analyzed by Western blot. NHFs were infected with KOS (or 
HA32) at an moi of 5 and harvested at 4, 6, 12 and 24 hpi (Figure 4-7). In the 
samples treated with GSH, the IE gene ICP4 shows no decrease in expression at 4 
hpi when compared to untreated. ICP4 is the major viral transcription factor 
responsible for activating E  and  late  gene  expression  as  well  as  repressing  the   
	  	   120	  
 
2 hpi
Mock
4 hpi
6 hpi
12 hpi
Topro3 ICP8 Merge
Topro3 ICP8 Merge
Untreated 20 mM GSH
Figure 4-6 Replication compartment formation is delayed in the presence of GSH. NHFs were 
infected with KOS at an MOI of 5 and incubated in MEM supplemented with 2.5% FBS with or without 2o 
mM GSH. Samples were fixed in 4% PFA at the indicated times. Cells were permeabilized in 1% Triton-tx 
and stained with anti-ICP8 antibody (middle panels). The DNA dye, Topro3, was used to stain cell nuclei 
(blue). 
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Figure 4-7 Late and true-late protein expression are delayed during GSH 
treament. NHFs were infected with KOS at an MOI of 5 followed by incubation 
in MEM containing 2.5% FBS with or without 20 mM GSH. Samples were 
harvested in reducing SDS sample buffer and resolved by SDS-PAGE. Proteins 
were detected by immunoblotting with the indicated antibodies.
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expression of IE genes, including itself (DeLuca and Schaffer 1985). Interestingly, at 
12 and 24 hpi, ICP4 expression appears more robust in the GSH treated samples 
than in the untreated samples suggesting its auto-regulatory activity might be 
impaired in the presence of GSH. The observation that ICP4 is expressed to equal 
levels at 4 hpi suggests that the viral genome entered the nucleus in GSH-treated 
cells and is expressing at least one IE gene. On the other hand, the E gene ICP8 
showed a delay in appearance and decreased levels, with detectable levels being 
observed beginning at 12 hpi compared to 4 hpi in untreated cells. Furthermore, the 
true-late gene, UL32, shows almost no detectable signal even at 24 hpi. In all, these 
data suggest that in GSH-treated cells the viral genome is able to enter the nucleus, 
express the first wave of viral genes but that there is a defect in E and L gene 
expression. Since our results showed that antioxidant treatment blocked replication 
compartment formation, as well as E and L gene expression, we hypothesized that 
HSV-induced ROS is important for an early step in the viral lifecycle.  
 
The NOX inhibitor DPI inhibits viral growth 
 
Next, we set out to explore the mechanism behind HSV-1 induced ROS 
generation.  Since NOXs are the main source of deliberate ROS generation and are 
known to play a major role in other viral infections, we hypothesized that NOXs 
might be important for HSV infection. To test whether NOXs are responsible for the 
HSV-induced ROS generation, we used the pan-NOX inhibitor, diphenylene 
iodonium (DPI). DPI has been reported to attenuate ROS generation in HSV-
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infected neural cells; however, this study did not examine the consequences of this 
treatment on viral growth (Hu, Sheng et al. 2011). NHFs were infected with KOS at 
an MOI of 0.1 and incubated in media containing 5, 10 or 20 uM DPI. The equivalent 
amount of DMSO in the highest (20 uM) dose was added to a control infection (total 
concentration of 0.2%). Figure 4-8 shows that at 5 uM DPI, the viral yield was 
decreased by over 500-fold at 12 hours with a somewhat less, but still substantial, 
decrease at 24 and 48 hpi. Similar results were obtained using HEL cells (data not 
shown). At 10 uM, the decreases in viral yield are over 1000-fold at every time point 
and even more substantial in cells treated with 20 uM. In order to test the effects of 
MOI on DPI-mediated inhibition, NHFs were infected at an MOI of 5 and treated as 
described above. Figure 4-9 shows that the effects of DPI treatment were not 
overcome at high MOI.  The decrease in virus production observed in the presence 
of DPI appears to mimic the growth defects seen in GSH-treated cells at both high 
and low MOIs. 
 
DPI treatment results in delayed formation of replication compartments 
 
 We next wanted to examine replication compartment formation during DPI 
treatment. NHFs were infected with KOS at an MOI of 5 and treated with media 
containing DMSO or 10 uM DPI. We collected the samples at 2, 4 and 6 hpi to 
monitor early events in the viral lifecycle. Again, ICP8 staining served as the marker 
for replication compartment formation. In the DMSO control samples, the number of 
cells that displayed replication compartments progressed from a few at 2 hpi to the  
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Figure 4-8 DPI treatment impairs growth of KOS on NHFs at low MOI. NHFs were infected 
with KOS at an MOI of 0.1 and incubated in MEM containing 15% serum with or without varying 
concentrations of DPI (see legend). Samples were collected at the specified timepoints and 
growth was measured by titration on Vero cells.
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Figure 4-9 DPI treatment impairs growth of KOS on NHFs at high MOI. NHFs were infected with 
KOS at an MOI of 5 and incubated in MEM containing 15% serum with or without varying concentra-
tions of DPI (see legend). Samples were collected at the specified timepoints and growth was measured 
by titration on Vero cells. 
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entire field at 6 hpi. Conversely, in the DPI treated samples, ICP8 staining was very 
weak compared to the control at each time point. Furthermore, ICP8 fluorescence 
was found in the cytoplasm in the DPI treated cells, compared to the predominant 
nuclear staining in the controls. The presence of cytoplasmic ICP8 was surprising 
and may indicate that either a nuclear import pathway is perturbed, or that ICP8 
itself is affected by DPI treatment. Thus, much like the GSH treated samples, 
replication compartment formation is substantially delayed with DPI treatment. 
In this experiment, we also followed NOX4, as a surrogate NOX, to see if it 
was upregulated during infection. In Figure 4-10, NOX4 staining was very weak in 
the mock - infected samples, although the fluorescence was slightly brighter in the 
DPI treated samples. Interestingly, in the untreated cells, NOX4 fluorescence 
increased at 2 hpi; at 4 and 6 hpi, NOX4 staining was visible in large juxtanuclear 
bodies. NOX4 also appeared to colocalize with ICP8 within replication 
compartments. In the DPI treated cells, however, NOX4 staining was mostly diffuse 
throughout the cell, even when ICP8 staining was nuclear.  Since NOX4 has been 
described as an ER membrane protein (Chen, Kirber et al. 2008), the perinuclear 
accumulation observed during infection is not surprising and the increasing intensity 
may just reflect upregulation of the protein. It is striking, though, that we observed 
NOX4 staining in nuclear replication compartments. We are intrigued by the 
possibility that the virus hijacks NOX4 and relocalizes it to sites where oxidation 
might be important. To explore this further, we will first need to confirm that during 
infection, the antibody is recognizing NOX4 exclusively and not cross-reacting with a 
viral epitope.  
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Figure 4-10 DPI treatment delays replication compartment formation. NHFs were infected 
with KOS at an MOI of 5 and incubated in MEM containing 15% FBS with or without 10 mM DPI. 
Cells were fixed in 4% PFA at the indicated times, permeabilized in 1% Triton-tx  and stained with 
antibodies against NOX4 and ICP8.
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DPI treatment impairs viral gene expression 
  
The defect in viral replication compartment formation led us again to test viral 
protein expression during DPI treatment. NHFs were infected with KOS at an MOI of 
5 and incubated in media containing DMSO, 5 uM or 10 uM DPI. Cells were 
harvested at 3, 6, 9 and 21 hpi in 2x SDS sample buffer. We observed that ICP4 
expression could be detected at 3 hpi in both the treated and untreated samples, 
although the untreated sample appeared more robust (Figure 4-11). ICP8 
expression, on the other hand, is severely delayed with no detectable expression 
until 6 hpi. Although it appears that there is somewhat less ICP4 expression at every 
time point in the treated samples, this likely wouldn’t account for the significant delay 
in ICP8 expression. What is striking, though, is the difference in the migration pattern 
of the ICP4 between the untreated and the treated samples. ICP4 is extensively 
modified during infection (Wilcox, Kohn et al. 1980, Papavassiliou, Wilcox et al. 
1991). These modifications, such as phosphorylation and ADP-ribosylation, have 
been shown to play a role in its regulatory functions. In the untreated samples 
(Figure 4-11), there is a slight mobility shift beginning at 6 hpi, whereas, the ICP4 in 
the DPI-treated samples appears to migrate at or near the same position at all of the 
time points analyzed. These results suggest that inhibiting NOX activity not only 
attenuates E and L gene expression, but also may alter the phosphorylation status 
of the major viral transcription factor, ICP4. Collectively, these data show that both 
antioxidant treatment and inhibition of cellular NOXs inhibits viral growth at an early  
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Figure 4-11 DPI treatment delays viral protein expression. NHFs 
were infected with KOS at an MOI of 5 followed by incubation in MEM 
containing 15% FBS with or without 5 uM or 10 uM DPI. Samples 
were harvested in reducing SDS sample buffer and resolved by 
SDS-PAGE. Proteins were detected by immunoblotting with the 
indicated antibodies.
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stage of infection, with both conditions delaying replication compartment formation 
and altering gene expression.  
 
  
Discussion 
 
In this study several important and novel findings were reported: 1) a 
genetically-coded redox probe was used to confirm that the intracellular environment 
was oxidized in HSV-infected cells; 2) GSH treatment was inhibitory to viral infection 
in Vero cells, but this was dependent on culture conditions; 3) GSH treatment 
inhibited viral growth on HeLa cells, and to a greater extent, NHFs and HEL cells at 
both low and high MOIs; 4) GSH-mediated inhibition was observed at an early stage 
of infection and correlated with a delay in replication compartment formation and E 
and L protein expression; 5) treatment with a NOX inhibitor (DPI) reduced viral 
growth;  and 6) DPI treatment severely attenuates replication compartment formation 
and L protein expression. In summary, these data are consistent with the hypothesis 
that HSV-1 induces and requires a pro-oxidant environment for efficient infection.  
In our initial experiment we used a redox-sensitive GFP system to detect the 
presence of intracellular ROS. Previous reports showing HSV-induced ROS used 
the redox-sensitive probes DCHF-DA (Schachtele, Hu et al. 2010, Gonzalez-Dosal, 
Horan et al. 2011, Hu, Sheng et al. 2011) or HPF (Kavouras, Prandovszky et al. 
2007). Although these dyes are routinely used, they suffer from lack of specificity 
and inadvertent reactions with non-ROS molecules. Even more alarming is that the 
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oxidation of these probes can lead to ROS as a by-product, thus resulting in an 
overestimation of intracellular ROS. Redox-sensitive GFPs (roGFPs) were designed 
to overcome these deficits as they are engineered to react with particular species 
and they don’t create ROS when oxidized. Newer generation roGFPs are linked to 
specific redox systems. For example, Grx1-roGFP2 is linked to the GSH:GSSG 
redox couple and has been used to determine the GSH redox potential in subcellular 
compartments. Another probe, roGFP2-Orp1, is linked to a peroxiredoxin and 
therefore measures intracellular H2O2. In our study, we used roGFP2 to measure the 
intracellular redox state. We confirmed previous reports that ROS are detected 
within 1 hpi and are sustained for up to at least 5 hpi (Figure 4-1). Our lab is 
currently generating stable cell lines expressing roGFP2-Orp1 and Grx1-roGFP2. 
These will be used to measure HSV-induced H2O2 generation and the GSH redox 
potential, respectively. We are also interested in examining cells expressing these 
probes during infection using fluorescence microscopy. These data will provide 
significant insight into the spatial and temporal regulation of ROS during HSV 
infection. 
 During this study, we were initially unable to reproduce previous reports that 
GSH treatment reduces HSV growth in Vero cells and HFFs (Palamara, Perno et al. 
1995, Vogel, Cinatl et al. 2005). We then analyzed the differences in our protocols 
and discovered that while we used DMEM as our basal media, the other reports 
used MEM and RPMI-1640 for their cell culture. We cultured Vero cells in MEM for 
several passages and found that GSH treatment inhibited HSV growth under these 
conditions. One possibility to explain this discrepancy is that DMEM is supplemented 
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with twice the amount of amino acids and vitamins that are found in MEM or RPMI-
1640. It is possible that these extra components induce a robust stress response in 
Vero cells that is sufficient to abrogate the protection offered by GSH. For instance, 
if activating a stress response is important for viral infection, and if this activation is 
prevented by GSH, then it might be possible for the culture conditions to induce 
activation of that stress response even in the presence of GSH. Our lab has 
observed that the heat shock protein, Hsc70, accumulates in the nucleoli of our Vero 
cells cultured in DMEM. Nucleolar accumulation of Hsc70 is a marker of cells that 
are recovering from stress (Banski, Mahboubi et al. 2010). Thus, under our typical 
culture conditions, our Vero cells appear to be in a stressed, or near-stressed state.  
Another possibility is that DMEM, unlike MEM and RPMI-1640, is 
supplemented with ferric nitrate, which is a source of iron. Ferric iron can be reduced 
to ferrous iron in the presence of strong reducing agents in solution. Ferrous iron is 
then able to undergo Fenton chemistry, which generates the extremely reactive 
hydroxyl radical. It is possible that the addition of 20 mM GSH could drive this 
supplemental iron into a free-radical generating redox cycle. This might induce ROS 
in the media and abrogate the effects of exogenous GSH treatment. It is also 
possible that GSH uptake is not as efficient in Vero cells cultured in DMEM. 
Additional experiments will be needed to determine which of these possible reasons 
can explain the difference in GSH sensitivity observed in cells grown in DMEM vs 
MEM. Whatever the reason, it is important that issues like these are considered 
when designing and interpreting redox-related experiments. 
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 Several human cell lines were selected to confirm that GSH treatment was 
inhibitory for viral growth. For these experiments, we selected two immortalized cell 
lines, NHFs and HeLa cells, and one primary cell line, HEL cells. We found that viral 
growth was most significantly inhibited in NHFs and HEL cells. Viral yields were 
reduced by over 99% in these cell lines at 12 hpi when infection was carried out at 
an MOI of 0.1. The viral growth defect was even more pronounced during GSH 
treatment when the cells were infected at an MOI of 5. Viral growth was inhibited by 
90% at 6 hpi, which suggests a much earlier defect in growth than the initial report 
by Palamara, et al (Palamara, Perno et al. 1995). In that study, they reported that 
GSH inhibited a late stage (24 hrs) of infection based on the following observations: 
1) a viral growth defect was detected at 24, 48 and 72 hpi, 2) neither protein nor 
DNA synthesis were perturbed at 24 hpi in the presence of GSH, 3) EM analysis 
showed accumulation of intranuclear capsids in GSH treated cells and 4) using a 
polyclonal anti-HSV antibody, they reported that a band that corresponds to 
glycoprotein B (gB) is not expressed in GSH treated cells, which would prevent the 
egress of the capsids from the nucleus. Their overall conclusion was that GSH 
treatment inhibited viral growth by preventing gB expression.  
In addition to the early growth defect, we observed a marked delay in E and L 
protein expression in GSH-treated cells with the first detectable levels of the E gene 
ICP8 seen at 12 hpi versus 4 hpi in the untreated cells. Our Western blot data are 
consistent with our immunofluorescence data showing a dramatic delay in replication 
compartment formation in GSH-treated cells. Although our results aren’t in full 
agreement with those previously reported, it should be noted that there are major 
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differences in the designs of these two studies. Palamara, et al only examined viral 
growth at 24, 48 and 72 hpi, which missed important time intervals that we included 
in our study (6 and 12 hpi). Furthermore, they looked at viral DNA and protein 
synthesis, using [3H] thymidine and [35S] methionine, respectively, at 24 hpi. Again, 
our study included looking at several proteins by WB and IF at much earlier times, 
giving us a more precise picture of when GSH treatment would exert an inhibitory 
effect. Thus, the differences in our conclusions are most likely a result of the 
differences in time points observed and the types of experiments performed. Our 
data suggest that GSH blocks infection at an early stage of infection.   
One of the more interesting revelations in this study is the efficient expression 
of the immediate early gene ICP4 in GSH-treated cells, but a delay in early proteins 
and an absence of a true late protein (Figure 4-6). This implies that early gene 
expression is sensitive to the intracellular redox balance. This finding raises several 
interesting possibilities.  Are viral transcription factors themselves redox regulated? It 
is interesting to consider that ICP4, the major viral transcription factor, is regulated 
by redox. To test this, an ICP4 reporter assay could be used to measure its 
regulation in the presence or absence of GSH. It is also possible that another 
regulatory gene is regulated by redox. A likely candidate would be the IE gene 
ICP27. ICP27 has been shown to work in coordination with ICP4 and another IE 
protein, ICP0 in the activation, as well as the repression of a subset of genes 
(Sekulovich, Leary et al. 1988, Samaniego, Webb et al. 1995). Interestingly, ICP27 
has also been shown to induce oxidative stress (Kim, Choi et al. 2008, Salaun, 
MacDonald et al. 2010) and to activate the stress kinases NF-kB, Jnk and p38 
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(Zachos, Clements et al. 1999, Hargett, McLean et al. 2005, Hargett, Rice et al. 
2006). It is possible that ICP27 modulates the activating and repressing activities of 
ICP4 through inducing cellular kinases. This strategy is not unusual for viruses. For 
instance, in the case of HIV, ROS induce viral gene transcription by activating the 
transcription factor NF-kB. Furthermore, blocking NF-kB activation with antioxidant 
treatment prevents viral gene transcription (Nabel and Baltimore 1987, Staal, 
Roederer et al. 1990). Here, a similar mechanism could be involved where GSH 
treatment is preventing the activation of a cellular stress kinase that is required for 
efficient E and L gene transcription.  
The most intriguing finding is that inhibiting NOX activity caused cells to be 
refractory to viral infection. The NOX family of proteins are increasingly being 
recognized as contributors to the pathogenesis of many viruses, including hepatits 
C, HIV and influenza (de Mochel, Seronello et al. 2010, Song, Ju et al. 2011, Vlahos, 
Stambas et al. 2011, Amatore, Sgarbanti et al. 2015). These viruses are also 
sensitive to antioxidant treatment (Fraternale, Paoletti et al. 2009). This study is the 
first, to our knowledge, to implicate a role for NOXs in HSV infection. Using a 
traditional pan-NOX inhibitor, we showed that viral growth was significantly 
decreased and that this defect correlated with a decrease in viral replication 
compartment formation and protein expression. Thus, like cells treated with GSH, 
early and late gene expression is reduced, RC formation impaired and viral yields 
decrease.  On the other hand, some differences in these experiments should be 
noted. For instance, the accumulation of cytoplasmic ICP8 in DPI treated cells 
(Figure 4-10) was surprising and not observed during GSH treatment (Figure 4-6). It 
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is possible that DPI treatment prevented the efficient intranuclear transport of ICP8. 
Another possibility is that ICP8 itself is sensitive to a reducing environment. Our lab 
has observed that ICP8 is sensitive to oxidation and can form disulfide-mediated 
crosslinks in the presence of H2O2 (data not shown). A property of ICP8 is that it 
forms filaments which appear to be required for the formation of replication 
compartments (Darwish, A., et al, unpublished). Thus, it is possible that NOX-
derived ROS contributes to ICP8 conformation or self-interactions in order for 
efficient filament formation. This might explain the presence of NOX4 in viral 
replication compartments. However, we will need to perform a similar study of 
replication compartment formation in cells that have been depleted of NOX4 
(through shRNA knockdown) to confirm that the antibody we used is recognizing 
NOX4 and not another cellular or viral protein that accumulates in replication 
compartments.  
We also observed that DPI treatment decreased the mobility shift in ICP4 
(Figure 4-11) during DPI treatment; whereas, GSH treatment resulted in 
overexpression of ICP4. The phosphorylation status of ICP4 is important for its 
regulatory functions (Papavassiliou, Wilcox et al. 1991). This limited shift in mobility 
suggests the possibility that ICP4 phosphorylation was inhibited when NOX activity 
was prevented. These results are preliminary, but we are intrigued by the idea that 
NOX-derived ROS activates stress kinase pathways. Even more exciting would be 
the possibility that these kinases are responsible for phosphorylating ICP4 to 
regulate the gene cascade. Although there were some slight differences in our 
results when comparing the two treatments, it is obvious that facilitating a reducing 
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environment, either by treatment with antioxidants or by inhibiting ROS generation, 
is deleterious for viral growth. In fact, it is rather striking that these two treatments 
exhibit so many similarities.  
In this study, we have taken a comprehensive look at the role of ROS during 
HSV-1 infection. Since Palamara, et al, first reported the relationship between HSV 
and ROS in 1995, only a few studies have examined this. Several have reported 
indirect markers of ROS, such as the accumulation of carbonylated (oxidized) 
proteins (Mathew, Bryant et al. 2010) or decreases in intracellular GSH (Nucci, 
Palamara et al. 2000, Vogel, Cinatl et al. 2005), while others have directly measured 
oxidation with fluorescent dyes (Schachtele, Hu et al. 2010, Kavouras, 2007 #247, 
Gonzalez-Dosal, Horan et al. 2011, Hu, Sheng et al. 2011). Our experiments are 
consistent with those of others suggesting that HSV-1 requires a pro-oxidant 
environment. Since similar results have have been reported in many other non-
related viruses, regardless of their genome, replicative cycle or other properties, we 
suggest that evolving to survive and thrive in an oxidizing environment is a common 
strategy for pathogens. It is likely that ROS were originally generated in cells to 
combat infection. Since ROS contribute to genetic mutations, this cellular antiviral 
response could actually be advantageous for the virus. Genetic mutations have been 
shown to be necessary for increasing the fitness of viruses (Pfeiffer and Kirkegaard 
2005). Thus in the interplay of virus and host, ROS, which originally served as a 
potent antiviral, may now be more beneficial for viruses than for their hosts.  
In summary, we conclude that HSV-1 growth is impaired if ROS levels are 
attenuated, either through the addition of antioxidants or through preventing 
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intracellular sources of ROS generation. Since early gene transcription and 
replication compartment formation are impaired when cellular ROS are prevented, 
we propose that HSV-1 generated ROS are mediators of signaling cascades that 
allow for the proper regulation of viral gene transcription. Future directions will be 
aimed at solidifying the role of cellular NOXs during infection. We will need to use 
inhibitors that target the NOXs more specifically, such as VAS2870 (Wingler, 
Altenhoefer et al. 2012). Also, a more targeted approach will be needed to define 
which NOXs, if any, are required for viral infection. Which NOXs are expressed in 
our cell types and how does their expression change during infection? Quantitative 
PCR analysis would allow monitoring of the transcription of all of the NOX family 
members during infection. Thus, candidate NOXs could be identified and 
investigated more thoroughly. Although not fully complete, the data we have 
presented has given us an exciting new avenue to pursue.  
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Chapter 5 
 
Summary and Perspectives 
 
 A number of pathogens, viral and bacterial, induce oxidative stress (OS) upon 
infection (Beck, Handy et al. 2000, Fraternale, Paoletti et al. 2009, Paiva and Bozza 
2014). Since reactive oxygen species (ROS) have the potential to cause damage to 
most macromolecules, OS would be a potent way to combat pathogens. In fact ROS 
is a common cellular response to infection and are produced by stimulated 
macrophages and other immune cells to clear pathogens.  Interestingly, it now 
appears that many pathogens have evolved to use increases in ROS for their own 
benefit. It is surprising that tolerance and even preference for an oxidizing 
environment has been shown in many organisms including viruses and bacteria 
(Beck, Handy et al. 2000, Fraternale, Paoletti et al. 2009, Paiva and Bozza 2014).  
 The interplay between virus and host has gone on through millennia. 
Understanding how viruses have evolved to use specific cellular pathways not only 
gives us a snapshot of the biological processes that have shaped the virus and host, 
but have also proven to be useful in designing therapeutics. For instance, HIV 
therapies have come a long way since the first reverse-transcriptase inhibitors were 
developed (Zolopa 2010), but treatment doesn’t cure infection due to a reservoir of 
cells harboring latent virus (Shan and Siliciano 2013). Current research is aimed at 
reactivating latent HIV, which in combination with anti-retroviral therapy could cure 
HIV by depleting these reservoirs. Yang, et al, found through a high throughput 
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screen that the compound 5-hydroxynapthalene-1,4-dione reactivated latent HIV by 
generating ROS (Yang, Xing et al. 2009), thus underscoring the importance of 
understanding the virus-ROS relationship. 
 The goal of the work presented in this thesis was to provide insight into the 
induction and consequences of HSV-1 induced ROS. In the process, we uncovered 
some unexpected, and exciting, new ways in which the virus might benefit from ROS 
through disulfide bond formation. We also discovered that the viral DNA packaging 
protein, UL32, is a possible oxidoreductase, which would allow the virus to cope with 
the increasingly pro-oxidant environment. Lastly, we presented evidence that 
preventing ROS through inhibition of cellular pro-oxidant enzymes, or treatment with 
antioxidants, inhibited infection at an early stage and may be linked to a regulatory 
role in gene expression. Thus this thesis has advanced our understanding of how 
HSV may use and cope with the intracellular redox balance to establish infection. 
 
Disulfide bond formation is important for HSV-1  
 
 In Chapter 2 we showed that disulfide bond formation was essential for the 
formation and stability of the UL6 portal ring (Albright, Nellissery et al. 2011).  
Consistent with this, another report from our lab showed that disulfide bond 
interactions were ubiquitous throughout the capsid (Szczepaniak, Nellissery et al. 
2011). Only one other paper showed the presence of disulfide bonds in HSV capsid 
proteins (Zweig); however, we were the first to illustrate the role these interactions 
were playing. Furthermore, we were able to map the cysteines responsible for the 
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UL6 portal ring formation and stability. A surprising observation was that the UL6 
portal possibly formed disulfide bonds in the nucleus. Although we knew that HSV-1 
had the potential to make the cell more oxidizing, we did not know the extent of the 
oxidation nor that oxidation occurred in the nucleus. The presence of disulfide bond 
formation in the nucleus suggests that the nucleus is oxidized to such an extent 
where these interactions could occur. This work leads to some important questions. 
How oxidized is the nucleus during infection? How is it being oxidized? How are 
these disulfide bonds formed? And most importantly, why are these disulfides 
present? One of the most important characteristics of a virus is that it must be 
metastable. The virion has to protect the genome from a harsh extracellular 
environment, but also be able to free the genome at the proper place. We propose 
that disulfide bonds within the capsid and portal serve as molecular sensors, and 
that they are destabilized once the virus enters the reducing environment of the host 
cell cytoplasm (Figure 5-1).  
 
HSV-1 encodes a redox-sensitive chaperone  
 
 Prior to the work presented in thesis, the role of UL32 had not been clear. It 
has always been associated with the DNA packaging step based on the fact that 
UL32-null mutants have no defect in protein or DNA synthesis, can form capsids but 
do not cleave package DNA (Schaffer, Aron et al. 1973, Lamberti and Weller 1998, 
Albright, Kosinski et al. 2015). When we examined the primary peptide sequence, 
we found a series of conserved motifs we believed could tell us more about possible 
functions of the protein. A UL32 homologue was identified in every herpesvirus we 
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Figure 5-1 Model for disulfide bonds as molecular sensors to trigger genome release. 1) Viral capsids egress 
from the nucleus of an HSV-1 induced oxidized cell. Disulfide bonds are formed and stabilize the capsid. 2) The 
capsid remains oxidized in the extracellular environment. 3) Upon entry, the viral capsid is exposed to the reducing 
environment of the cell and begins to destabilize as it’s trafficked to the nucleus. 4) reduction of disulfide bonds 
within the UL6 portal and/or the viral capsid trigger the release of the genome into the nucleus. 
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examined, and even more interesting, almost all of these homologues had 
conserved C-X-X-C motifs (Figure 3-3). C-X-X-C motifs are found in redox-sensitive 
proteins, such as thioredoxin and other oxidoreductases, and have been shown to 
be involved in regulating disulfide bond formation through a two-step dithiol-disulfide 
exchange reaction (Figure 5-2)(Chivers, Laboissiere et al. 1996, Chivers, Prehoda et 
al. 1997, Fomenko and Gladyshev 2003). This observation led us to test the 
hypothesis that UL32 is a redox-sensitive protein that influences disulfide bond 
formation in viral proteins.   
If true, the presence of a virally encoded oxidoreductase would be a 
remarkable evolutionary strategy to survive in a pro-oxidant environment. Reactive 
cysteines that can form disulfide bonds are found ubiquitously throughout the capsid 
and it is probable that an oxidizing environment would cause a lot of aberrant 
disulfide bonding to occur. Thus, we provide an example of a protein that may allow 
HSV to cope with this problem.  We generated a UL32-null virus and found that in 
the absence of UL32, aberrant disulfide bond formation was observed in several of 
the capsid proteins. Of all of the proteins that exhibited differential disulfide bond 
formation in the absence of UL32, the UL6 portal and the viral protease, VP24, were 
of the most interest. Both of these proteins are absolutely essential for the DNA 
packaging reaction which is consistent with the defect seen in the UL32 null. The 
fact that VP24 had a different disulfide bond profile in the absence of UL32 is very 
intriguing. It has been shown that the viral protease in another human herpesvirus, 
CMV, contains reactive cysteines and its proteolytic activity is regulated by disulfide 
bonds (Baum, Ding et al. 1996, Baum, Siegel et al. 1996). Our results suggest that  
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UL32 UL32 UL32
Fig. 5-2 Model for UL32 oxidoreductase activity. In a standard dithiol-disulfide exchange reaction, an 
oxidoreductase enzyme will interact with a disufide bonded substrate. One cysteine in the conserved 
C-X-X-C motif is extremely reactive and forms a disulfide bond with one of the cysteines in the substrate 
forming a mixed disulfide. This is followed by the formation of a disulfide bond between the two cysteines 
within the C-X-X-C motif of the oxidoreductase with the complete reduction of the substrate. 
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VP24 may also be regulated by disulfide bonds which opens up an entire new area 
of research. During viral DNA packaging, there is a complex series of events that 
involves the translocation of the genome into the viral capsid and a cleavage and 
release of the internal scaffold; however, the order of these events and what triggers 
them is not understood at all. The idea that disulfide bonds regulate proteolysis of 
the internal scaffold is another example of how the redox environment serves an 
important role in the lifecycle of HSV. It will be important to determine whether UL32 
directly modulates disulfide bonds in VP24 to trigger this event, or if it plays a 
peripheral role. In 2003, a genome-wide proteomic screen revealed 23 potential viral 
oxidoreductases in nature, with all of them belonging to dsDNA viruses (Kho, 
Newman et al. 2003), however the vaccinia virus oxidoreductase has been the only 
one, to our knowledge, that has been validated and studied. In this system, there are 
three viral proteins (E10R, A2.5L and G4L) which participate in a thiol-disulfide relay 
responsible for modulating disulfide bonds in the cytoplasm (Senkevich, White et al. 
2002). It would be interesting to see if UL32 is involved in a similar chain. Thus, the 
work presented in this thesis not only is the first to describe a putative virally-
encoded oxidoreductase in HSV, but is also the first to suggest disulfide bond 
formation as a regulator in viral protease activation.  
 
 
HSV-1 induced oxidative stress may play a role in gene regulation 
 
In Chapter 4, we follow up on previous work showing that HSV induces the 
generation of ROS and the virus is sensitive to antioxidant treatment (Palamara, 
Perno et al. 1995, Nucci, Palamara et al. 2000, Vogel, Cinatl et al. 2005, Schachtele, 
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Hu et al. 2010, Hu, Sheng et al. 2011, Qiu, Chen et al. 2013). In this study, we 
showed that antioxidant treatment blocked HSV infection at an early stage of 
infection. Furthermore we show that the virus is able to express immediately early 
proteins (the first wave) in the presence of GSH, but that early and late proteins 
aren’t expressed as efficiently. We also observed a similar defect in viral growth by 
inhibiting ROS-generating enzymes, more specifically the NADPH-oxidases (NOXs). 
NOX inhibition also led to a delay in the formation of viral replication compartments. 
In all these data suggest that ROS, possibly generated by NOXs, might be important 
for an early stage of infection between immediate early gene expression and early 
gene expression.  
The results summarized above suggest that it is possible that HSV-induced 
ROS stimulate gene transcription through activating redox-sensitive transcription 
factors. If so, this would be reminiscent of the role ROS play during HIV infection. It 
has been shown that ROS activate the transcription factor NF-kB, which upregulates 
the expression of HIV genes (Nabel and Baltimore 1987, Staal, Roederer et al. 
1990). The exciting observation that HSV-1 might induce ROS for regulating its own 
gene transcription has several implications. It is known that stress reactivates HSV 
from latency, however, the reasons for this have not been fully worked out. In 2009, 
it was shown that the viral transcription factor VP16 was required for reactivation 
from latency and that the VP16 promoter was activated in the presence of 
hyperthermic stress in the absence of other viral proteins (Thompson, Preston et al. 
2009). Furthermore, a much older paper reported that VP16 is responsible for 
activating the p38/Jnk pathways (Zachos, Clements et al. 1999). Is it possible that 
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VP16 expression is ROS dependent during lytic infection? It has also been shown 
that the immediate early protein ICP27 induces ROS and the activation of NF-kB. 
ICP27 is also a regulator of late gene expression (Hargett, McLean et al. 2005, 
Hargett, Rice et al. 2006, Kim, Choi et al. 2008, Li, Johnson et al. 2008, Salaun, 
MacDonald et al. 2010). Thus, HSV-1 induced ROS might work on multiple levels to 
facilitate the onset and progression of lytic infection.  
 
 
 
Final thoughts and future directions 
 
 The work presented here has led us to propose the following model. We 
suggest that upon infection, the viral capsid is exposed to a reducing cytoplasmic 
environment, which destabilizes the capsid and possibly the portal, triggering the 
release of the genome through the nuclear pore. During this time, the virus induces 
a change to a more oxidizing state, potentially through cellular NOXs, which results 
in the activation of viral transcription factors to regulate early and late gene 
expression. During lytic infection, viral structural proteins are made and transported 
to the nucleus. As these capsid proteins have a lot of reactive cysteines, the viral 
oxidoreductase, UL32, uses a dithiol-disulfide exchange reaction (Figure 5-2) to 
prevent aberrant disulfide bond formation and to allow the assembly of capsids that 
are competent for encapsidation. Furthermore, we propose that UL32 might also 
regulate the viral protease, triggering its activation at some step of the packaging 
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process to allow the release of the internal scaffold. This model is preliminary, 
however, and will require a lot more work to be validated.  
 The ubiquitous presence of disulfide bonds throughout the capsid and in the 
portal is interesting but there are significant gaps in our knowledge as to when and 
where they form. We have observed disulfide bond formation in the portal ring in 
capsids isolated from the nucleus. The viral capsid proteins, on the other hand, 
seem to form disulfide bonds only when they are in mature virions in the extracellular 
environment (Szczepaniak, Nellissery et al. 2011). Interestingly, UL32 has a unique 
cellular distribution during infection. It is located within replication compartments at 
early times, consistent with its role in DNA encapsidation, but then accumulates in 
the cytoplasm at later times. It is then possible that UL32 keeps the egressing 
capsids in a reducing state until they reach the extracellular environment. Since 
UL32 is not present in the extracellular virion, this would allow the disulfide bonds 
within the capsid to form. Since the defect in UL32 is at the packaging step, it is 
impossible to test this hypothesis using a UL32 null. There is, however, a 
temperature sensitive UL32 virus that could be used for such a study. For instance, 
cells could be infected at the permissive temperature until the packaging reaction is 
complete, and then shifted to the non-permissive temperature, thus abrogating its 
function. This would allow us to assign a post-packaging role to UL32. If it was 
involved in keeping the disulfide from forming in the cytoplasm, the predicted result 
from this experiment is that we would detect disulfide bond formation in capsids 
earlier than previously published (Szczepaniak, Nellissery et al. 2011). It would also 
be important to show that UL32 does in fact interact with the viral capsid. Generating 
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a UL32 mutant virus in which one of the cysteines within the C-X-X-C motif is 
mutated would be a possible way to test this. As can be seen in Figure 5-2, both 
cysteines participate in the dithiol-disulfide exchange. If the second cysteine in this 
reaction was mutated, there would be no resolution of the mixed disulfide, thus 
trapping UL32 with its partner. The most exciting experiments, however, would be 
testing whether UL32 was responsible for regulating protease activity. It was 
previously reported that incubation of the protease in various solvents and anions 
stimulated its activity by several fold (Hall and Darke 1995). These data suggest that 
the these conditions allowed for a conformational change in the protease, most likely 
by allowing a buried hydrophobic pocket to be exposed, which regulated its activity. 
It would be exciting if a similar protease assay could be used to test the hypothesis 
that UL32 modulates disulfide bonds within the protease to induce a conformational 
change, thus leading to its activation.  
 Another exciting result presented in this thesis is the idea that HSV-1 induced 
ROS, possibly through NOXs, is important for the proper regulation of gene 
expression. The results in this thesis are very preliminary, but our results suggest 
that viral infection is blocked at an early step in the presence of antioxidants or if 
NOX activity is blocked with a chemical inhibitor. First, we need to establish how 
HSV induces ROS. Although we showed a block in infection using a pan-NOX 
inhibitor, it would be important to show that NOXs are in fact inducing ROS. For this 
line of research, an expression profile should be done on all of the NOX family 
members during infection. It has been shown that upregulation of NOX expression is 
correlated with NOX activity (Amatore, Sgarbanti et al. 2015). Thus, this would allow 
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us to select candidate NOXs for shRNA knockdown studies to confirm their role in 
HSV infection. Infected NOX knockdown cells could be monitored for ROS 
generation, viral protein expression and viral growth. It would also be important to 
test whether mitochondrial ROS contributes to HSV-1 infection. This could be done 
using Mito-Tempo, which is an antioxidant that is targeted to the mitochondria. 
Furthermore, it would be exciting to link the ROS to activation of specific pathways 
that might influence viral gene expression. It would be interesting to identify all of the 
proteins that are associated with the viral genome during infection with and without 
antioxidant treatment. It would be exciting if stress-related transcription factors were 
associated with specific promoters, which could be done using chromatin immune-
precipitation (ChIP), during normal conditions but absent in the presence of 
antioxidants. ChIP could also be used during inhibition or knockdown of NOXs.  
 In this thesis, we have explored, and found many novel links between HSV 
and oxidative stress.  As exciting as these results are, they have only set the stage 
for a much more comprehensive body of work. The role of oxidative stress in viral 
infection will undoubtedly gain momentum with increasing technologies and it will be 
exciting to see how the results from these studies contribute to our understanding of 
virology, cell biology and to diseases in which oxidative stress plays a significant 
role.  
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